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ABSTRACT 
Information on the pathogenesis and tissue distribution of Atypical Bovine Spongiform Encephalopathy (BSE) 
in cattle through the study of field cases and experimental transmission studies is lacking. The latter are limited 
to transmission of Atypical BSE through intracerebral (i.c.) inoculation of cattle. All data currently available 
relate to the presence or absence of PrP
Sc, but do not quantify relative amounts of PrP
Sc or levels of infectivity. A 
laboratory protocol for further studies is recommended, to allow the assessment of the relative infectious titre, 
PrP
Sc accumulation and prion seeding activity in the tissues of cattle that developed H-BSE or L-BSE (using 
posterior brainstem as a reference). Tissues to be covered by those studies are categorised in three priorities, 
based on their inclusion in the list of specific risk material in cattle, on the presence of infectivity, or PrP
Sc 
presence,  demonstrated  in  Atypical  BSEs  or  other  Transmissible  Spongiform  Encephalopathies  (TSEs)  in 
ruminants, and on the importance in terms of input into the food chain in the EU. The protocol provides details 
in terms of the minimum number of animals to be tested, processing and preparation of tissues, and methods to 
be used to identify abnormal PrP and quantify infectivity, also depending on the expected level of infectivity and 
amount of tissue available for analysis. It is recommended that, through the implementation of the protocol, 
information  should  also  be  obtained  on  the  performance  of  currently  validated  rapid  tests  for  TSE  active 
surveillance in cattle/bioassay for detecting H-BSE and L-BSE agents. 
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SUMMARY 
Following  a  request  from  the  European  Commission,  EFSA  was  asked  to  provide  scientific  and 
technical  assistance  on  a  protocol  for  further  laboratory  investigations  into  the  distribution  of 
infectivity of Atypical Bovine Spongiform Encephalopathy (BSE). 
The European Union Reference Laboratory (EURL) for Transmissible Spongifom Encephalopathies 
(TSEs) conducted experiments (referred to as the EURL study) that resulted in the collection and 
storage of reference material originating from cattle experimentally infected with Atypical BSE (H-
BSE and L-BSE). With the intention to generate relevant data that could inform further policy options 
regarding BSE, in particular as regards rules on specified risk material (SRM), DG SANCO wished to 
explore the possibility to submit these tissue samples to further investigations. EFSA was therefore 
asked to propose a laboratory protocol to perform new studies aimed at investigating the presence, 
distribution and relative level of infectivity of Atypical BSE (H-BSE and L-BSE). EFSA was also 
expected to reflect on whether the tissues available from the EURL study are sufficient for the purpose 
and/or suggest that investigations on other tissues might be possibly needed. 
Data relating to the prevalence and geographical distribution of Atypical BSE in the European Union 
(EU) are incomplete and subject to variation owing to the ongoing retrospective typing of BSE cases. 
So far, 80 cases of Atypical BSE have been reported by EU Member States from 2001 to 2014. All 
Atypical BSE cases have been detected by active surveillance, typically in animals over eight years of 
age, with a similar number of cases detected each year. 
This report provides an overview of the biological material collected from field cases of Atypical BSE 
and transmission studies, both in the framework of the EURL study and additional published scientific 
studies. It was concluded that information on the pathogenesis and tissue distribution of Atypical BSE 
in cattle through the study of field cases and experimental transmission studies is lacking. The latter 
are limited to transmission of Atypical BSE through intracerebral (i.c.) inoculation of cattle. Where 
data  exist  from  both  field  cases  and  experimental  animals  (i.e.  for  L-BSE  only),  there  is  good 
agreement of the data with regard to abnormal PrP distribution. There are no data for field case H-
BSE. All data currently available relate to the presence or absence of PrP
Sc, but do not quantify 
relative amounts of PrP
Sc or levels of infectivity. 
Approaches to quantify Atypical BSE prions in cattle tissues are described and reviewed, including 
bioassay and in vitro methods. 
A laboratory protocol for further studies is recommended. Its application would provide elements 
allowing the assessment of the relative infectious titre, PrP
Sc accumulation and prion seeding activity 
in the tissues of cattle that developed H-BSE or L-BSE (using posterior brainstem as a reference). 
Tissues to be covered by those studies were categorised in three priorities, based on their inclusion in 
the cattle SRM list, on the presence of infectivity, or PrP
Sc presence, demonstrated in Atypical BSEs or 
other TSEs in ruminants, and on the importance in terms of input into the food chain in the EU. The 
protocol provides details in terms of the minimum number of animals to be tested, processing and 
preparation of tissues, and methods to be used to identify abnormal PrP and quantify infectivity, also 
depending on the expected level of infectivity and amount of tissue available for analysis. 
Applying the protocol only to the tissues obtained through the EURL study would provide information 
on some but not all the tissues from the cattle SRM list. It would also provide information on some 
additional tissues not included in the cattle SRM list, but relevant for the food chain. Material from 
other  studies  could  be  used  to  augment  the  range  of  SRM  and  non-SRM  tissues  available.  It  is 
acknowledged that there is no identified source able to provide all the samples necessary to assess 
infectivity in tissues belonging to the full cattle SRM list in H- and L-BSE-infected animals, and 
therefore, to complete this objective, new inoculation experiments with H- and L-BSE agents in cattle 
would have to be considered. Recommendations on general principles for such new experiments are 
provided. Atypical BSE study protocol 
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In  accordance  with  former  EFSA  recommendations,  it  is  recommended  that,  through  the 
implementation of the protocol, information should also be obtained on the performance of currently 
validated rapid tests for TSE active surveillance in cattle/bioassay for detecting H-BSE and L-BSE 
agents. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
While the annual number of Classical BSE cases in the EU continues to decrease, more knowledge 
regarding Atypical BSE (H and L types) appears desirable in order to envisage further policy options 
regarding BSE control. 
In 2009 and 2011, at the request of the European Commission’s Directorate General for Health and 
Consumer  Protection (DG  SANCO),  the  European Union  Reference  Laboratory  (EURL) for TSE 
(AHVLA in the United Kingdom) was tasked to carry out experiments to produce reference material 
for the EURL and for National Reference Laboratories. In total 12 cattle were inoculated, of which 4 
with BSE Н-type and 4 with BSE L-type in 2009, and 2 with BSE Н-type and 2 with BSE L-type in 
2011. Various tissue samples of these infected cattle were collected by the EURL and stored for future 
use. 
Some of these tissue samples have already been tested by the EURL, with at least one laboratory 
method,  as  shown  in  the  table  in  Annex  1
4  More detailed information regarding protocols and 
experimental results is included in Annex 2
4. 
With the intention to generate relevant data that could inform further policy options regarding BSE, 
DG SANCO wishes to explore the possibility to submit these tissue samples to further investigations. 
The purpose of the new experiments would be to generate additional data on the presence, distribution 
and relative level of infectivity of Atypical BSE (H and L types) in the infected cattle from the EURL 
study. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA is therefore asked, in accordance with Article 31 of (EU) Regulation 178/2002, for scientific 
and  technical  assistance,  i.e.  to  propose  a  laboratory  protocol  to  perform  new  studies  aimed  at 
investigating the presence, the distribution and the relative level of infectivity of Atypical BSE (H and 
L types) in these tissues. 
We would like you to deliver this technical assistance by 30 June 2014. EFSA is requested to liaise 
with the EURL for TSE to facilitate further exchanges of information. 
Clarification of the terms of reference 
It was clarified that: 
  The overall intention of the further investigations would be to generate relevant data that could 
inform further policy options regarding BSE, in particular as regards SRM rules. 
  The EFSA report is expected to reflect on whether the tissues available from the EURL study are 
sufficient for the purpose and/or suggest that investigations on other tissues might be possibly 
needed. 
   
                                                       
4 Annexes 1 and 2 to the mandate. Atypical BSE study protocol 
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ASSESSMENT 
1.  Introduction 
The  large-scale  testing  of  nervous  tissues  from  ruminants  for  the  detection  of  Transmissible 
Spongiform Encephalopathies (TSEs) has led to the recognition of two molecular signatures distinct 
from Classical Bovine Spongiform Encephalopathy (BSE) (C-BSE) in cattle. These were termed H-
BSE and L-BSE, also known as  Bovine Amyloidotic  Spongiform Encephalopathy  (BASE). Their 
PrP
Sc  molecular  signature  differed  from  C-BSE  in  terms  of  protease-resistant  fragment  size  and 
glycoform  pattern  (Biacabe  et  al.,  2004;  Casalone  et  al.,  2004;  Buschmann  et  al.,  2006).  The 
experimental transmission of these cases to different lines of bovine prion protein (PrP) transgenic 
(Tg) mice unambiguously demonstrated their infectious nature and most often confirmed their unique 
but distinctive strain phenotype compared with C-BSE (Beringue et al., 2006; Buschmann et al., 2006; 
Beringue et al., 2007; Capobianco et al., 2007). 
In the following sections, a brief description of the epidemiology, pathogenesis and transmissibility to 
animal models of Atypical BSE is given. In particular, information provided by EFSA in the past 
(EFSA BIOHAZ Panel, 2011; EFSA, 2012) is summarised and updated with new evidence that has 
become available in the last few years. 
1.1.  Epidemiology 
Until recently, typing of cattle BSE cases was not required by European Union (EU) legislation. From 
July 2013, Regulation (EC) No 999/2001
5 was amended to  require that samples from BSE-positive 
cattle are submitted for TSE classification. Retrospective typing of past BSE cases is also currently 
ongoing in some EU Member States.  Information on BSE type distribution in the EU  is therefore 
incomplete. It originates from data available in the scientific literature (Jacobs et al., 2007; Stack et al., 
2009) and data reported by Member States to the European Commission on an ad hoc basis (“EU BSE 
databases”). 
Scientific studies report information on the identification of L-BSE in France (Biacabe et al., 2008), 
Italy (Casalone et al., 2004), Germany (Buschmann et al., 2006), Great Britain (Stack et al., 2013) and 
Poland (Polak et al., 2008). H-BSE has been reported in France (Biacabe et al., 2008), Great Britain 
(Terry et al., 2007), Germany (Buschmann et al., 2006), the Netherlands (Jacobs et al., 2007) and 
Sweden (Gavier-Widen et al., 2008). Outside the EU, Atypical BSE has been also reported in Japan 
(Yamakawa et al., 2003; Masujin et al., 2008), the USA (Richt et al., 2007), Canada (Dudas et al., 
2010) and Switzerland (in a zebu (Seuberlich et al., 2006)). 
Data on Atypical BSE cases reported in the EU BSE databases since 2001 are presented in Tables 1 
and 2. As indicated above, typing data are incomplete and thus should be considered with caution. In 
particular, not all EU Member States have provided information on the typing of detected BSE cases, 
and for other countries the proportion of typed cases is variable. By 2015, these data might be more 
comprehensive following a request from the European Commission to Member States for re-testing 
and retrospective classification of all positive bovine isolates in the EU in the years 2003–2009. 
 
                                                       
5   Regulation (EC) No 999/2001 of the European Parliament and of the Council of 22 May 2001 laying down rules for the 
prevention, control and eradication of certain transmissible spongiform encephalopathies. OJ L 147, 31.5.2001, p. 1, as 
last amended. Atypical BSE study protocol 
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Table 1:   Number of Atypical BSE cases reported by EU Member States in the period 2001–2014 by country and by type (L- and H-BSE) (extracted from 
EU BSE databases on 1 July 2014). By 2015, these data might be more comprehensive following a request from the European Commission to Member States 
for re-testing and retrospective classification of all positive bovine isolates in the EU in the years 2003–2009 
BSE type  Country   2001  2002  2003  2004  2005  2006  2007  2008  2009  2010  2011  2012  2013
(a)  2014
(a)  Total 
H-BSE  Austria                    1          1 
France
(b)  1  2  3        1  2  2  2      2    15 
Germany        1                    1  2 
Ireland    1                1  2    1    5 
The Netherlands  1                            1 
Poland            1      1            2 
Portugal                      1        1 
Spain                      1  1      2 
Sweden            1                  1 
United Kingdom          1    1    1    1    1    5 
Total  2  3  3  1  1  2  2  2  4  4  5  1  4  1  35 
L-BSE  Austria              1      1          2 
Denmark        1                      1 
France
(b)    1  1  1  1  2  1  3  2  1    1      14 
Germany    1                        1  2 
Italy    1  1        1    1    1        5 
The Netherlands    1  1              1          3 
Poland    1    2  2  1  2        1  2  1    12 
Spain                        2      2 
United Kingdom              1      1  1  1      4 
Total  0  5  3  4  3  3  6  3  3  4  3  6  1  1  45 
Total Atypical cases (H + L)  2  8  6  5  4  5  8  5  7  8  8  7  5  2  80 
(a):  Data for 2013-2014 are incomplete and may not include all cases/countries reported. 
(b):  France has performed extensive retrospective testing to classify BSE cases, which is probably the explanation for the higher number of Atypical BSE cases reported in this country. 
   Atypical BSE study protocol 
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Table 2:   Number of Atypical BSE cases reported by EU Member States in the period 2001–2014 by type (L-, H- and C-BSE) and target group (extracted 
from EU BSE databases on 1 July 2014). By 2015, these data might be more comprehensive following a request from the European Commission to Member 
States for re-testing and retrospective classification of all positive bovine isolates in the EU in the years 2003–2009 
BSE type  Target group  2001  2002  2003  2004  2005  2006  2007  2008  2009  2010  2011  2012  2013
(a)  2014
(a)  Total 
H-type  Healthy slaughtered animals  1  1  1  1    1      1  1    1  1  1  10 
Fallen stock  1  2  2    1  1  2  2  2  3  5    3    24 
Emergency slaughter                  1            1 
L-type  Healthy slaughtered animals    4  1  1  2  2  1    1  1  2  3  1  1  20 
Fallen stock    1  2  2  1  1  5  2  2  3  1  3      23 
Emergency slaughter        1        1              2 
C-BSE  Healthy slaughtered animals  282  294  270  175  113  78  39  29  26  13  7  4      1 330 
Fallen stock  400  608  404  312  218  165  91  72  28  23  13  7  2    2 343 
Emergency slaughter  321  512  318  172  125  31  8  6  2            1 495 
(a):  Data from 2013-2014 are incomplete and may not include all cases/countries reported. 
 Atypical BSE study protocol 
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The number of Atypical BSE cases detected in countries that have already identified them seems to be 
similar from year to year. In France, a retrospective study of all TSE-positive cattle identified through 
the compulsory EU surveillance between 2001 and 2007 indicated that the prevalence of H-BSE and 
L-BSE was 0.35 and 0.41 cases per million adult cattle tested, respectively, which increased to 1.9 and 
1.7 cases per million, respectively, in tested animals over eight years old (Biacabe et al., 2008). No 
comprehensive study on the prevalence of Atypical BSE cases has yet been carried out in other EU 
Member States. 
All  cases  of  Atypical  BSE  reported  in  the  EU  BSE  databases  have  been  identified  by  active 
surveillance testing (59 % in fallen stock, 38 % in healthy slaughtered cattle and 4 % in emergency 
slaughtered cattle). Cases were reported in animals over eight years of age, with the exception of two 
cases (one H-BSE and one L-BSE) detected in Spain in 2011/2012. One additional case of H-BSE was 
detected in Switzerland in 2012 in a cow born in Germany in 2005 (Guldimann et al., 2012). 
The generally older age of the identified H-BSE and L-BSE cases, and their apparently low prevalence 
in the population, suggest that these Atypical BSE forms could be arising spontaneously. 
1.2.  Pathogenesis 
The  putative  origin  of  Atypical  BSEs  (sporadic  vs.  acquired)  influences  the  extent  to  which 
information gathered from experimental studies may represent the real distribution of the agent in the 
body  of  naturally  affected  cattle.  Intracerebral  (i.c.)  challenge  would  be  an  appropriate proxy  for 
studying the distribution of the agent if the origin of the disease was spontaneous, and originating in 
the brain, while oral challenge would be more appropriate if the origin of the disease was through 
ingestion of infected material. 
To date there is no comprehensive information about the pathogenesis of Atypical BSEs in cattle. 
Some data are available on the peripheral distribution of H- and L-BSE agents in cattle experimentally 
challenged by the i.c. route, but all of the animals in these studies were allowed to develop clinical 
disease.  Information  available  from  published  studies  on  the  transmissibility  and  distribution  of 
infectivity in tissues of cattle challenged in those experiments are reported in Sections 2.1 and 2.2. No 
results are currently available for oral transmission experiments of Atypical BSE to cattle. An oral 
transmission study was initiated by oral challenge of cattle with L-BSE brain homogenate in January 
2008 (Panelli et al., 2011), but final results on transmissibility and infectivity distribution are not yet 
available. The fact that field cases are detected overwhelmingly through active surveillance has also 
greatly restricted data available on tissue distribution in natural disease, and such data are available 
only for L-BSE. 
The current lack of information on the distribution of infectivity in tissues of Atypical BSE-infected 
cattle does not allow judgement of whether the current list of bovine specified risk material (SRM), set 
by EU legislation based on data relating to the pathogenesis and tissues distribution of C-BSE, is fit 
for the purpose of removing most of the Atypical BSE infectivity from bovine carcasses. 
1.3.  Transmission studies in animal models other than cattle 
Both L-BSE and H-BSE agents are able to propagate in experimentally challenged foreign species. 
There is a wider host susceptibility for L-BSE, with transmissions demonstrated in mice, sheep, voles, 
primates and hamsters, as well as in transgenic mice expressing heterologous, i.e. non-bovine, PrP 
sequences,  whereas  H-BSE  has  not  yet  proven  transmissible  to  sheep,  hamsters  or  humanised 
transgenic mice. 
Proof of principle of the ability of L-BSE to propagate in sheep was provided by the i.c. propagation 
of  an  L-BSE  isolate  in  ARQ/ARQ  sheep  and  also  in  transgenic  mice  expressing  the  ovine  PrP
C 
variants. The propagation of L-BSE in sheep seemed to result in a TSE with a different profile to that 
of C-BSE (Nonno et al., 2008; Nicot et al., 2014). L-BSE isolates transmitted to transgenic mice 
expressing ovine PrP
C (Beringue et al., 2007), or inbred wild-type mouse lines (Capobianco et al., Atypical BSE study protocol 
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2007),  acquired  a  phenotype  indistinguishable  from  the  BSE  agent.  However,  the  inoculation  of 
tissues collected from mice over-expressing ovine PrP
C, inoculated with C-BSE and L-BSE, to bovine 
PrP
C transgenic mice resulted into two different phenotypes specific to each agent, suggesting that the 
agents passaged in ovine PrP transgenic mice, although producing a similar signature in the brain, 
were actually different (Beringue et al., 2010). 
Transmission of H-BSE isolates originating from France and Poland to bovine PrP transgenic mice has 
been reported. While in the majority of the cases the propagated TSE was different from C-BSE, C-
BSE has emerged in a proportion of the mice inoculated with two distinct isolates (one from France 
and one from Poland) (Torres et al., 2011). Baron et al. (2011) also observed strain features similar to 
C-BSE after inoculation of conventional mice with H-BSE. 
Together  these  data  indicate  that  there  may  be  an  aetiological  relationship  between  Atypical  and 
Classical BSE. 
Intracerebral inoculation of brain tissue from L-BSE-infected cattle to cynomolgus macaques induced 
a spongiform encephalopathy distinct in all its aspects (clinical, pathological and biochemical) from 
macaque BSE (Comoy et al., 2008). Incubation periods were shorter for L-BSE (23–25 months) than 
for C-BSE (38–40 months), suggesting that L-BSE may be more virulent than C-BSE for infecting 
primates. L-BSE was also transmissible to microcebus, with shorter incubations than C-BSE (Baron et 
al., 2008). Moreover, experiments demonstrated the transmissibility of L-BSE to macaques by the oral 
route (Comoy, 2010). L-BSE was transmitted with success also to mouse lemurs, another primate 
model, after both i.c. and oral inoculation, with a longer incubation period and less severe clinical 
symptoms following oral challenge (Mestre-Francés et al., 2012). 
Histology  and  biochemistry  studies  showed  similarities  between  L-BSE-inoculated  macaques  and 
MM2 sporadic Creutzfeldt–Jakob disease (sCJD) patients: infected primates and those rare patients 
exhibited similar lesional profiles, and the disease-specific PrP from both groups showed the same N-
terminal protease sensitivity. Moreover, a macaque inoculated with brain tissue from a MM2 sCJD 
patient showed a similar lesion profile to L-BSE-infected macaques (Comoy et al., 2009). Similarly, 
transmission of L-BSE into bank voles resulted in a TSE with phenotypic characteristics (incubation 
period,  PrP
Sc  biochemical  properties  and  vacuolar  lesion  profiles)  indistinguishable  from  those 
observed after transmission of a VV2 sCJD case in this rodent model (Nonno et al., 2009). 
The i.c. inoculation of L-BSE field isolates produced TSE disease in two lines of mice over-expressing 
human PrP (Met129), exhibiting a molecular phenotype distinct from that of C-BSE (Beringue et al., 
2008a; Kong et al., 2008). In one of them, the L-BSE agent appeared to propagate with no obvious 
transmission barrier: a 100 % attack rate was observed on first passage, the incubation time was not 
reduced on subsequent passaging (Beringue et al., 2008a) and the L-BSE PrP
Sc biochemical signature 
was  essentially  conserved  (Beringue  et  al.,  2008a;  Kong  et  al.,  2008),  appearing  to  be 
indistinguishable from that seen after experimental inoculation of MM2 sCJD in these mice (Beringue 
et al., 2007). These transmission features markedly differed from the low transmission efficiency of 
cattle C-BSE isolates to this (Beringue et al., 2008a; Beringue et al., 2008b) and other (Asante et al., 
2002; Wilson et al., 2012) human PrP transgenic mouse lines, based on the presence of clinical signs 
and/or protease-resistant prion protein (PrP
res) in the brain (Beringue et al., 2012). 
H-BSE isolates failed to infect one line of “humanised” mice (Met129 PrP) (Beringue et al., 2008a). 
These mice over-express human PrP and were inoculated i.c. with a low dilution inoculum, supporting 
the view that the transmission barrier of H-BSE from cattle to humans (expressing this allele) might be 
quite robust. 
The permissiveness to Atypical BSEs of “humanised” transgenic mice expressing the valine allele at 
codon 129 is currently unknown. Atypical BSE study protocol 
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1.4.  Detection of infection 
Limited data are available on the performance of the validated rapid tests used for cattle TSE testing 
for the detection of Atypical BSE cases, in terms of either their analytical sensitivity or their ability to 
detect infected asymptomatic animals. This results in uncertainty about the true prevalence of these 
conditions.  However,  Meloni  et  al.  (2012)  compared  the  analytical  sensitivity  of  EU-approved 
commercial TSE rapid tests for C-BSE, H-BSE and L-BSE, and, although some differences in the 
analytical sensitivity were reported, all tests succeeded in detecting the three BSE forms at a 1:16 
dilution prepared following the manufacturers’ instructions. 
In C-BSE cases, pathogenesis studies have established that abnormal PrP deposition in the brainstem 
first occurs at the obex level, where substantial amounts of this disease-specific protein accumulate 
during the late incubation phase (Arnold et al., 2007; Wells et al., 2007; Simmons et al., 2010). As a 
consequence, targeting of the brainstem at the level of the obex for C-BSE rapid testing is considered 
to be the most sensitive approach for detecting cases within the framework of the active surveillance 
system. 
In Atypical BSE (both H- and L-BSE), the suitability of the obex as the target tissue for testing that 
would allow an early and sensitive detection of these conditions remains questionable, although all the 
Atypical  BSE  cases  detected  so  far  have  been  identified  through  the  active  surveillance  system, 
indicating that obex testing with currently validated tests allows the detection of at least a proportion 
of these cases. 
When  discriminating  the different  forms  of  BSE,  immunohistochemistry  (IHC)  in  brain  has  been 
reported to allow discrimination of distinguishable immunolabelling patterns for C-BSE, L-BSE and 
H-BSE, especially when focusing on rostral areas of the brain, and cerebellum (Konold et al., 2012). 
Western blotting (WB) allows prompt identification of H-BSE cases according to the molecular mass 
of the unglycosylated PrP fraction and the detection of the protein by antibodies binding to N-terminal 
epitopes (e.g. SAF32, P4); L-BSE can be identified by the lower molecular mass of the unglycosylated 
PrP fraction and the altered glycoprofile (similar quantities of di- and monoglycosylated PrP). This 
WB classification is the method currently stipulated in the EU TSE Regulation. 
1.5.  Concluding remarks 
  Data relating to the prevalence and geographical distribution of Atypical BSE are incomplete 
and subject to variation owing to the ongoing retrospective typing of BSE cases. 
  All Atypical BSE cases have been detected by active surveillance, typically in animals over 
eight years of age, with a similar number of cases detected each year from 2001 to 2013. 
  The recent cessation of the testing of healthy slaughtered cattle in some EU Member States 
will lead to a loss of capacity of the monitoring system to detect Atypical BSE cases. 
  Sampling  and  rapid  testing  procedures,  as  currently  performed,  have  not  been  formally 
evaluated for the detection of Atypical BSE and might have an impact on the capacity to 
monitor the epidemiological situation of the disease. 
  Information on the pathogenesis and tissue distribution of Atypical BSE in cattle through the 
study of field cases and experimental transmission studies is lacking. The latter are limited to 
transmission of Atypical BSE through i.c. inoculation of cattle. 
  For  transmission  studies,  i.c.  challenge  would  be  an  appropriate  proxy  for  studying  the 
distribution of the agent if the origin of the disease was spontaneous, and originating in the 
brain, while oral challenge would be more appropriate if the origin of the disease was through 
ingestion of infected material. 
  The current lack of information on the distribution of infectivity in tissues from Atypical BSE-
infected cattle does not allow judgement of whether the current list of bovine SRM, set by EU Atypical BSE study protocol 
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legislation based on data relating to the pathogenesis and tissue distribution of C-BSE, is fit 
for the purpose of removing most of the Atypical BSE infectivity from bovine carcasses. 
  As is the case for C-BSE, Atypical BSE (H-BSE and/or L-BSE) agents are able to propagate 
in  experimentally  challenged  foreign  species  such  as  mice,  sheep,  voles,  primates  and 
hamsters, and in transgenic mice expressing heterologous, i.e. non-bovine, PrP sequences. 
2.  Biological material collected from field cases and transmission studies in cattle 
2.1.  Information available from published literature 
Intracerebral transmission studies in cattle with both Atypical BSE forms have been performed at 
different institutes. Lombardi et al. (2008) described the i.c. challenge of six cattle with L-BSE and, as 
a  control,  six  cattle  with  C-BSE.  The  clinical  signs  were  described  and  the  PrP
Sc  distribution  in 
different brain regions and the spinal cord were analysed. A follow-up study by Suardi et al. (2012) 
reported on the presence of BSE infectivity and PrP
Sc deposition in peripheral muscle samples taken 
from these L-BSE challenged cattle. 
A similar study was performed in Japan, in which the first Japanese L-BSE isolate was used for an i.c. 
challenge experiment in five cattle (Fukuda et al., 2009). It could be shown by WB analysis that 
numerous peripheral nervous tissues contained PrP
Sc (Iwamaru et al., 2010). In contrast, all samples 
from the lymphoreticular system turned out to be negative. A similar study was performed by the same 
group using a Canadian H-BSE isolate for the i.c. challenge of three cattle. As already shown for L-
BSE, the presence of PrP
Sc in various peripheral nervous tissues could be determined (Okada et al., 
2011b). 
In a different i.c. challenge study, five cattle were inoculated with L-BSE and six cattle with H-BSE 
(Balkema-Buschmann et al., 2011). The general restriction to the central nervous system (CNS) that 
had already been described for C-BSE was confirmed in these cattle. 
Intracerebral challenge studies with both Atypical BSE forms were also performed by Konold et al. 
(2012), in which PrP
Sc deposition was identified in muscle spindles and in the trigeminal ganglion 
following a limited study of potential peripheral distribution. This study is described in more detail in 
Section 2.2. 
There have also been a few field cases of L-BSE in which more extensive examination and collection 
of peripheral tissues was possible (Mazza et al., 2007; Suardi et al., 2012). 
2.2.  The European Union Reference Laboratory (EURL) study 
The  majority  of  Atypical  BSE  cases  so  far  identified  worldwide  have  been  detected  by  active 
surveillance.  Consequently,  the  volume  and  quality  of  material  available  for  the  underpinning  of 
confirmatory diagnosis and classification and the demonstration of robust statutory testing through 
external quality assessment (EQA) was very limited. This small cattle transmission study, of both H- 
and L-BSE, had the primary aim of providing tissue for test evaluation and research, and to generate 
clinical, molecular and pathological data in a standardised way to enable more robust comparison of 
the two variants with particular reference to those aspects most relevant to case ascertainment and 
diagnosis within existing regulated surveillance programmes. 
In  the  first  study  (Konold  et  al.,  2012),  groups  of  four  calves  (10–11  months  of  age)  were 
intracerebrally inoculated with 1.0 mL of either L-BSE or H-BSE brain homogenate (in 10 % w/v 
solution in sterile saline) prepared from a French cow with H-BSE (code: ESB-H-07-0644) and an 
Italian cow with L-BSE (code: 141387/02). Prior to inoculation, the inocula were either heat treated 
(twice for 15 minutes at 70 °C; H-BSE) or treated with antibiotics (L-BSE) according to established 
methods (Wells and Hawkins, 2004). Atypical BSE study protocol 
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The animals were kept until clinical signs developed, and these clinical signs were systematically 
monitored and described. All the animals presented with a nervous disease with some similarities to 
C-BSE, which progressed to a more dull form in one animal from each group. Difficulty rising was a 
consistent feature of both disease forms and was not seen in two BSE-free, non-inoculated cattle that 
served as controls. The animals were then killed and the brains removed to fulfil the primary tissue 
generation objective of the study. Limited pathology and molecular characterisation was undertaken to 
ensure that the diagnostic features of the experimentally generated material were representative of the 
original field case donor animals. A range of additional peripheral tissues (neural and non-neural) 
were taken, to generate matched tissue sets with material previously collected from animals challenged 
in a similar way with scrapie (Konold et al., 2006). These tissue sets were stored in the Defra TSE 
Archive for possible future research requests. A complete list of tissues collected and description of 
analyses already performed are provided in Table 3 (see also Appendix A). 
Following the requirement for all bovine TSE isolates arising within the EU to be classified, a further 
four animals (two H-BSE and two L-BSE) were challenged intracerebrally to augment the material 
available to the EURL for EQA and provision of appropriate controls for diagnostic investigations. 
These challenges were sub-passages of some of the primary challenge cases. Experimental donor 
material was chosen partly because of its provenance, with regard to relative microbiological stability 
and clinical status, and partly to establish that the phenotype of the disease remained stable following 
experimental passage. 
Each challenge was a single donor to a single recipient design, and the donors were chosen based on 
the greatest dissimilarity of clinical presentation in the primary challenges (i.e. one animal from each 
group which had shown a nervous clinical presentation and one with a dull presentation). All inocula 
were tested for bacterial contamination and treated with antibiotics if required. The recipient calves 
were seven months old at challenge. As for the primary challenges, animals were monitored until the 
development and description of clinical disease, at which point the animals were killed and the same 
tissue collection and disease characterisation protocols were applied. 
Part of this characterisation was the phenotypic description, but not titration, of the H- and L-BSE 
material in bovinised transgenic mice (tg110) both before and after each experimental passage. Some 
of these bioassays are still ongoing. 
   Atypical BSE study protocol 
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Table 3:   Material collected within the EURL study and related information on conservation status 
and testing performed 
Tissue  Status of material available  Testing performed 
Fixed  Frozen 
Central nervous system 
  Brain  x  x  IHC and WB positive  
  Spinal cord  x  x  IHC positive  
Peripheral nervous system - ganglia and plexi 
  Cranial cervical ganglion   x     
  Nodose ganglion   x     
  Stellate ganglion  x     
  Trigeminal ganglion  x  x  IHC positive  
Peripheral nervous system - nerves 
  Facial nerve   x     
  Radial nerve  x     
  Sciatic nerve  x  x   
  Splanchnic nerve  x     
  Sympathetic chain   x     
  Vago-sympathetic trunk   x     
  Vagus nerve  x     
Lymphoid tissue 
  Bronchomediastinal LN  x  x   
  Cervical thymus  x  x   
  Hepatic LN  x  x   
  Lateral retropharyngeal LN  x  x   
  Medial retropharyngeal LN  x  x  IHC negative 
  Mesenteric LN  x  x  IHC negative 
  Nictitating membrane  x     
  Palatine tonsil  x  x  IHC negative 
  Pharyngeal tonsil  x     
  Popliteal LN  x  x   
  Prefemoral LN  x  x   
  Prescapular LN  x  x   
  Submandibular LN  x  x   
  Spleen  x  x   
Gastrointestinal tissues 
  Cranial oesophagus  x  x   
  Distal ileum (Peyer’s patches)  x  x  IHC negative 
  Jejunum (Peyer’s patches)  x  x   
Muscles 
  Extra-ocular muscles  x  x  IHC positive  
  Medial gluteal muscle  x  x  IHC positive  
  Semitendinosus muscle  x  x   
  Triceps muscle  x  x  IHC positive  
Other tissues 
  Adrenal gland  x  x   
  Eye  x  x   
  Kidney  x  x   
  Parotid salivary gland  x  x   
  Sub-mandibular salivary gland  x  x   
Body fluids 
  Blood fractions     x   
  Cerebrospinal fluid    x   
LN, lymph nodes. Atypical BSE study protocol 
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2.3.  Additional information on material available 
Data available from the literature relating to field case examinations, the EURL study and the other 
transmission studies outlined above (Section 2.1) have been collated to provide a comprehensive list 
of the tissue samples that have been collected and examined from natural and experimental cases of H-
BSE and L-BSE. The full list is given in Appendix A and represents a wide range of tissues from both 
the central and peripheral nervous systems, the lymphoreticular system, the musculoskeletal system 
and the gastrointestinal tract, together with other principal edible organs. However, none of these 
studies was explicitly designed to address the issue of potential infectivity in the context of the current 
legislation on SRM, and so there are some SRM tissues that have not been collected within any of 
these studies, namely the duodenum, the jejunum and ileum (without Peyer’s patches), the caecum, the 
colon and the mesenteric fat. For these tissues there are therefore no data, and no possibility to create 
data without undertaking further experimental challenges. All of the experimental material is derived 
from animals that have been challenged intracerebrally. 
In total, data are available for 15 experimental H-BSE and 23 L-BSE cases, representing challenges 
with 4 donors respectively, while data on PrP distribution in naturally-occurring field cases have been 
published for only three L-BSE-affected cattle. 
There are no data for field case H-BSE. Where data exist from both field cases and experimental 
animals (i.e. for L-BSE only), there is good agreement  between the data with  and abnormal PrP 
distribution, with the CNS and muscles both consistently affected. However, these data relate to the 
presence or absence of PrP
Sc, and do not attempt to quantify relative amounts of PrP
Sc or levels of 
infectivity. 
Overall, disease-related PrP has been reported in CNS tissues, peripheral ganglia and nerves, muscles 
(predominantly muscle spindles), adrenal glands and retina for both H-BSE and L-BSE. By contrast, 
no lymphoid tissues or gastrointestinal tissues have tested positive by IHC, WB or bioassay. Some 
tissues have been collected, but with no testing outcome explicitly reported. 
Comparative data relating to C-BSE (see Appendix A, Table 12) are to a large extent fragmented, and 
have evolved over a long period as different analytical methods have been developed and applied. 
Many of the original infectivity data are based on conventional mouse bioassay rather than transgenic 
models so, although positive results are robust, negative results do not necessarily have the same 
sensitivity thresholds (see also EFSA BIOHAZ Panel (2014)). It must also be noted that data available 
for C-BSE are derived predominantly from field cases or oral challenge models. There are few data 
from i.c. challenge studies that can be directly compared with existing data for Atypical BSE. 
However, collective data indicate that C-BSE shares the same tissue distribution as the Atypical BSE 
cases, with PrP
Sc and/or infectivity detected in the central and peripheral nervous systems, including 
ganglia and nerves, and the muscle spindles in skeletal muscle. As in Atypical BSE, the adrenal glands 
and the retina are also affected. 
Additionally,  in  C-BSE  there  is  also  evidence  of  involvement  of  the  lymphoreticular  system, 
particularly, but not exclusively, in those tissues associated with the gastrointestinal tract. The PrP
Sc 
distribution and relative levels of infectivity in the gastrointestinal tissues were presented in detail in a 
previous EFSA Opinion (EFSA BIOHAZ Panel, 2014). Nasal mucosa and bone marrow have also 
been shown to contain infectivity. 
There  are insufficient  data  at  present to  be clear  about  whether these  apparent  differences in the 
distribution of disease-specific markers reflect absolute differences between C-BSE and the H-BSE 
and L-BSE variants, whether they are a consequence of detection threshold limitations, or whether 
they are a consequence of the different routes of challenge. Atypical BSE study protocol 
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2.4.  Concluding remarks 
  Where data exist from both field cases and experimental animals (i.e. for L-BSE only), there is 
good agreement of the data with regard to abnormal PrP distribution. There are no data for 
field case H-BSE. 
  All data currently available relate to the presence or absence of PrP
Sc, but do not quantify 
relative amounts of PrP
Sc or levels of infectivity. 
  Disease-related PrP has  been reported consistently in CNS tissues, peripheral ganglia and 
nerves, muscles (predominantly muscle spindles), adrenal glands and retina for both H-BSE 
and L-BSE. All of these tissues are also positive in C-BSE. 
  By contrast with C-BSE, at this stage no lymphoid tissues or gastrointestinal tissues from H-
BSE-  and  L-BSE-affected  animals  have  tested  positive  for  PrP
Sc  presence  (IHC,  WB)  or 
infectivity (bioassay). 
  There are insufficient data at present to be clear about whether these apparent differences in 
the distribution of disease-specific markers reflect absolute differences between C-BSE and 
the  H-BSE  and  L-BSE  variants,  whether  they  are  a  consequence  of  detection  threshold 
limitations, or whether they are a consequence of the different routes of challenge. 
  No studies have been explicitly designed to address the issue of Atypical BSE with respect to 
SRM regulations. Without further experimental challenges or tissue collection from ongoing 
studies it will not be possible to obtain any data on duodenum, the jejunum and ileum (without 
Peyer’s patches), the caecum, the colon and the mesenteric fat. 
3.  Generic approach to quantify Atypical BSE prions in cattle tissues 
3.1.  Bioassay 
Estimation  of  a  TSE  agent’s  infectivity  in  tissues  is  traditionally  determined  by  bioassay.  This 
involves the experimental inoculation of groups of animals either by the i.c. route only or by both the 
intraperitoneal (i.p.) and the i.c. route and the recording of the resulting disease attack rate, incubation 
period  and  the  percentage  of  inoculated  animals  that  develop  clinical  signs  and/or  accumulate 
detectable levels of abnormal prion protein in brain or peripheral tissues, to estimate the infectious 
titre. 
3.1.1.  Choice of the mouse model 
The  development  of  transgenic  mouse  models  for  the  PrP  gene  allowed  the  species  barrier  (a 
phenomenon  that  limits  TSE  agent  primary  passage  in  conventional  rodent  models)  to  be 
reduced/suppressed.  PrP  sequence  identity  between  the  transgenic  host  and  donor  are  usually 
associated with a higher transmission rate than in wild-type mice. A clear increase in transmission rate 
for the three BSE agents (C-BSE, L-BSE and H-BSE) was observed upon transmission in a gene 
targeted transgenic mouse line expressing the bovine prion protein (Bov6) when compared  with a 
wild-type  control  of  the  same  genetic  background  (Wilson  et  al.,  2013).  However,  the  low  PrP 
expression level of these gene-targeted Tgbov mouse models represents a major handicap for their use 
in prion detection. In fact, the long incubation times and the partial transmission rates in these mice 
inoculated with the three BSE agents highlight the low utility of these models for the detection of 
these agents. 
Several mouse lines over-expressing bovine PrPC have been developed: Tg(BoPrP) 4092HOZ (Scott 
et al., 1997), BoPrP-Tg110 (Castilla et al., 2003), Tgbov XV (Buschmann and Groschup, 2005), and 
TgBo-Tg540 (Beringue et al., 2006), and have shown good sensitivity for the detection of bovine 
prion infectivity. Several studies have shown that all three BSE agents are efficiently transmitted to 
these transgenic mice, showing neuropathological and molecular phenotypes that are distinct for each 
BSE agent (Beringue et al., 2006; Buschmann et al., 2006; Beringue et al., 2007; Capobianco et al., 
2007; Okada et al., 2010; Torres et al., 2011). In all cases, all three BSE agents were fully transmitted Atypical BSE study protocol 
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to these Tg-bov mouse models, although L-BSE showed survival times that were shorter (≈ 200 days) 
than H-BSE (≈ 250–300 days), but which were higher than those of C-BSE. 
Table 4 summarises transmission data available for each mouse model when inoculated with the three 
BSE agents. Although the isolates used were not the same for each mouse model, these data suggest 
that any of these mouse lines over-expressing bovine PrP are adequate for the detection of both L-BSE 
and H-BSE. 
Because  the  interspecies  transmission  of  prion  infection  is  essentially  governed  by  the  structural 
compatibility between recipient host PrP
C and the infecting PrP
Sc strain type(s) (Collinge and Clarke, 
2007), non-bovine PrP transgenic mouse lines or species might, in principle, be able to propagate 
bovine  BSE  prions  without  any  apparent  species  barrier.  This  has  been  exemplified  by  the  high 
susceptibility of the bank vole to sCJD (Nonno et al., 2006). 
Table 4:   Survival times (days) and transmission rates (%) of BSE agents in several mouse models 
Mouse line  C-BSE  L-BSE  H-BSE  Reference 
TgBo110  250–300 
(100 %) 
190–220 
(100 %)  
280–350 
(100 %) 
Torres  et  al.  (2011)  (see  also 
Appendix A) 
Tg(BoPrP) 
4092HOZ/Prnp
0/0  
243 ± 7 
(100 %) 
198 ± 34
a 
(100 %) 
316 ± 12 
(100 %) 
Okada  et  al.  (2011a);  Masujin 
(2008) 
Tgbov XV  250–300 
(100 %) 
200–215 
(100 %) 
322
 
(100 %)
 
Buschmann  et  al.  (2006); 
Capobianco et al. (2007) 
TgBo-540  300–380 
(100 %) 
210–230 
(100 %) 
400–415 
(100 %) 
Beringue  et  al.  (2006);  Beringue 
et al. (2007) 
Bo6 (knock-in mice)  518 ± 18 
(15/22) 
547 ± 18 
(2/24) 
561 ± 15 
(1/23) 
Wilson et al. (2012) 
129/Ola (wild-type 
mice) 
498 ± 43 
(8/8)  
NA (0/24)  NA (0/24)  Wilson et al. (2012) 
NA: no mice showed clinical signs of disease. 
3.1.2.  Bioassay results and infectious titre estimates 
When trying to estimate the infectious titre of a TSE agent in a sample using bioassay transmission 
results, several approaches can be used. 
3.1.2.1.  Endpoint titration approach 
The most straightforward and accurate approach to estimate the infectious titre in prion diseases is the 
Spearman–Karber  method.  In  this  approach,  groups  of  animals  are  challenged  with  successive 
dilutions of an inoculum and studied for the development of the disease and/or presence of detectable 
levels of PrP
Sc in brain or peripheral tissues. Infectious titre is assessed by the Spearman–Karber 
formula (Hamilton et al., 1977) and expressed as LD50 (lethal dose) or ID50 (infectious dose) per gram 
of inoculated tissue (where one LD50 or one ID50 corresponds to the amount of substance required to 
kill/infect 50 % of challenged animals). 
Spearman–Karber formula: log10LD50 = (X0 − [d/2]) + d(Σri/ni), where: 
X0 = log10 of the highest dilution at which all mice died of the disease 
d = dilution factor 
ri = number of positive mice in the X0 and subsequent dilutions 
ni = number of mice inoculated in the X0 and subsequent dilutions (discounting those dying 
from intercurrent deaths but taking into account those whose brains contained PrP
Sc but did 
not develop symptomatic disease) Atypical BSE study protocol 
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The model provides a maximum likelihood infectious titre (LD50 or ID50) and a confidence interval 
(CI)  (Markus  et  al.,  1995).  However,  to  provide  an  accurate  estimate  of  the  infectious  titre,  the 
Spearman–Karber method requires that at least one of the tested dilutions displays a 100 % attack or 
infection  rate.  This  requirement  makes  this  approach  unsuitable  for  estimating  titres  in  samples 
containing low infectivity. 
3.1.2.2.  Incubation period/attack rate derived models 
Although regarded as less accurate than the endpoint titration approach, dose–response relationships 
have been used as a method for infectivity estimation (Prusiner et al., 1982; Heikenwalder et al., 2007; 
Lacroux et al., 2008) when endpoint titration data are not available. 
For a given TSE agent (strain), the approach relies on: 
  the endpoint titration of a reference inoculum; 
  the  computation  of  a  dose-response  curve  reporting  for  a  given  incubation  period  the 
associated infectious titre of the inoculum; and 
  the use of this dose–response curve to estimate the infectious titre of other inocula on the basis 
of their inoculation in the reference animal model. 
More recently, Arnold et al. (2009) developed a method able to provide a more accurate estimation of 
the infectious titre than using attack rate alone and providing a natural way to deal with experimental 
animals  that  have  died  before  the  end  of  the  experiment  without  having  to  decide  debatable 
inclusion/exclusion criteria. The titre of infectivity is estimated using both the probability of survival 
(attack rate at each dilution) and the individual mouse incubation periods at each dilution using a 
Bayesian approach instead of the maximum likelihood approach. 
The method considers not only the incubation period observed in mice but also the possibility that an 
infected mouse could die from causes unrelated to BSE (e.g. intercurrent disease or sacrifice at the 
experimental endpoint) during the experiment. 
3.1.2.3.  Poisson distribution-derived models 
The use of the Poisson distribution to calculate the resulting titres and standard deviations in TSE 
agent inocula was initially used in the prion field to estimate the infectious titre in blood fractions 
prepared from infected mice  (Brown et al., 1998). The complete methodology is described in an 
appendix to the paper of Brown et al. (1999). The approach relies on the principle of the random 
distribution  of  physical  particles  in  low-concentration  solutions.  It  is  based  on  the  attack 
rate/transmission rate observed following inoculation of a known volume of inoculum to a group of 
animals and it does not require any reference (dose–response) to provide a titre estimate. The method 
has been extensively employed for measurements of infectivity in blood, blood components and urine 
of  TSE-infected  rodents  (under  the  denomination  “Limiting  Dilution  Titration”).  This  statistical 
approach can be applied to inocula which do not fulfil the criteria for the Spearman–Karber method 
application (at least one dilution infecting/killing 100 % of the animals). 
This approach also provides an estimate of the maximum infectious titre (upper boundary CI 95 %) 
that can be found in an inoculum when no transmission is observed in a bioassay experiment (Brown 
et al., 1999; Andreoletti et al., 2012). 
The Poisson calculation returns a value for the ID that can be converted into ID50 (Fisher, 1936; 
Gregori et al., 2006). Atypical BSE study protocol 
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3.1.3.  Overall considerations 
  Low, if any, infectivity is expected to be found in many of the cattle tissues. In this context, 
incubation period/attack rate and Poisson distribution-derived models appear to be the most 
suitable approaches for estimating the infectious titres in these tissues. 
  Estimate of maximum infectious titre in negatively bioassayed tissues: 
-  The amount of prion infectivity that is below the threshold of detectability of a mouse 
bioassay but that might be present in the studied tissue can be estimated in infectious units 
(IU) per millilitre with 95 % CI (rather than in 50 % infectious dose (ID50)) by assuming a 
Poisson distribution in the response variable, as proposed by Notari et al. (2012). 
-  More recently, Makarava et al. (2012) also proposed the use of the Poisson equation for 
determining prion infectivity which is present below the limit of detectability, although 
infectivity was expressed in ID50 (Makarava et al., 2012). This way, for the probability that 
a given inoculum dose contains no active particle, P(0), the Poisson equation reduces to: 
P(0) = e
–m 
where  m  is  the  concentration  of  the  active  particle  at  that  dilution  in  particles  per 
inoculation volume. 
The probability that there will be at least one active particle to initiate infection, P(≥1), is: 
P(≥1) = 1 – e
–m 
Infectivity data can be fitted to the expression: 
F = 1 – exp( –ax) 
where F is the fraction of infected animals, x is the dilution and a is the fitted parameter 
equal to the undiluted concentration of infectivity. 
ID50  can  be  calculated  by  solving  the  fitted  equations  for  F = 0.5  (infectivity),  which 
reduce to the expression: 
ID50 = –ln(0.5)∕a 
3.2.  In vitro amplification 
3.2.1.  In vitro amplification techniques 
Two very efficient procedures to amplify prions in a test tube have emerged in the last decade. Both 
rely on the detection of PrP structural conversion and polymerisation upon addition of PrP
Sc “seeds” 
contained in the infected samples (for a review see Kraus et al. (2013)). 
The protein misfolding cyclic amplification (PMCA) assay is based on repetitive cycles of incubation 
and sonication, using a PrP
C-containing substrate (in excess). Incubation of PrP
Sc seeds with PrP
C-
containing substrate is thought to favour PrP
C conversion and growth of PrP
Sc aggregates. Sonication 
is thought to fragment the polymers, thus multiplying the number of seeds for further conversion. The 
cyclic nature of the system and the possibility to refresh the substrate at each round  enables the 
performance of as many cycles as required to reach the amplification state needed for the detection of 
PrP
Sc in a given sample. Monitoring is performed by conventional Western blot or enzyme-linked 
immunosorbent assay (ELISA)-based techniques. PMCA allows the detection of minute amounts of 
PrP
Sc in biological tissues or fluid samples including blood, urine, faeces or cerebrospinal fluid from 
many prion-infected species (Castilla et al., 2005; Kurt et al., 2007; Lacroux et al., 2012). Atypical BSE study protocol 
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The  quaking-induced  conversion  (QuIC)  and  amyloid  seeding  assay  (ASA)  monitor  the 
conformational  conversion  of  soluble,  alpha-helix-rich  recombinant  PrP  (recPrP)  into  beta-sheet-
enriched amyloid-like fibrils following the addition of PrP
Sc (for a review see Orru et al. (2012)). 
Shaking instead of sonication is performed to break the generated polymers and provide new seeds for 
conversion. In its real-time, high-throughput format (RT-QuIC), prion-seeded amyloid formation of 
recPrP  is  followed  by  detection  of  thioflavin  T  (ThT)  fluorescence  over  time.  recPrP  substrate 
replacement has been reported to dramatically improve the QuIC sensitivity (Orru et al., 2011). The 
technique has proved sensitive in detecting prions in several infected tissues and in fluids such as 
cerebrospinal fluid, saliva, nasal fluids and blood (Safar et al., 2008; Atarashi et al., 2011; Orru et al., 
2011; McGuire et al., 2012). 
3.2.2.  Definition of the quantification approach of seeding activity 
These methods do not detect prion infectivity in a given tissue, but allow detection of a seeding 
activity potentially associated with prion replication. They can thus be considered on first intention as 
surrogate markers of prion infectivity (or prion seeding activity). Under defined conditions, these 
methods can be used to quantitatively estimate prion concentration in fluids and tissues of interest. 
In most PMCA protocols (Castilla et al., 2005), there is a direct relationship between the amount of 
PrP
Sc in the sample and the number of PMCA rounds necessary for detection. For quantification, the 
amplified PrP
Sc signal can be compared with that seen in endpoint titrated material run in the same 
conditions  (such  as  brain  homogenate  from  animals  at  the  terminal  stage  of  disease)  or  to  PrP 
calibration curves (Chen et al., 2010). 
By analogy with animal bioassays, both PMCA and RT-QuIC assays can titrate the seeding activity in 
endpoint diluted samples (Wilham et al., 2010; Makarava et al., 2012). For PMCA, this can be done 
over several rounds (Makarava et al., 2012) or in several independent experiments when maximal 
sensitivity  is  achieved  within  a  round,  i.e.  without  substrate  refreshment  (Moudjou  et  al.,  2013). 
Provided a sufficient number of replicates are performed (see below), it allows the establishment of a 
“seeding dose” giving positive responses in 50 % of replicate reaction (SD50). 
3.2.3.  Choice of the substrate 
In both PMCA and QuIC methods, the choice of the PrP substrate is a critical parameter for achieving 
efficient and sensitive amplification. 
For PMCA, the nature of the tissue that serves as the PrP substrate (brain, extraneural tissue, cells, 
etc.), the genetic background (notably for transgenic mouse lines expressing the PrP of interest), the 
primary structure of PrP
C and the level of PrP
C in the substrate have all been shown to strongly 
modulate PMCA sensitivity by several orders of magnitude (Mays et al., 2009; Mays et al., 2011; 
Moudjou et al., 2013). 
For QuIC, the conformational diversity of recombinant PrP from different animal species used so far 
as a substrate in QuIC assays remains poorly investigated. Hamster, human, chimeric human–hamster 
or  chimeric  sheep–hamster  recPrP  constructs  are  mostly  used  in  the  different  assays  reported, 
independently of the prion strain and species to be amplified (Atarashi et al., 2007; Atarashi et al., 
2011; Orru et al., 2011; McGuire et al., 2012). 
For both methods, the best PrP substrate may not be the one that is the most homologous (with regard 
to PrP primary sequence) to the type of prion to be assayed. 
3.2.4.  Repeatability and robustness 
Owing to the inconsistent amplification/fibrilisation observed in reactions seeded with highly diluted 
material, performing at least four or five replicates per sample and dilution is a critical parameter when 
assessing the minimal seeding activity in homogenates (Castilla et al., 2005; Makarava et al., 2012). Atypical BSE study protocol 
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3.2.5.  Availability of negative samples 
Because  of the  sensitivity  achieved  with  the cell-free techniques,  sometimes at the  sub-infectious 
level, the possibility of false-positive results due to cross-contamination is high  (Cosseddu et al., 
2011).  A  significant  number  of  negative  samples  must  be  tested  along  with  the  positive  ones  to 
exclude any cross-contamination. If there is any evidence of cross-contamination, the whole run must 
be discarded. 
Negative controls are also important to ensure that any potential inhibitory impact of the substrate of 
the tissue to be assayed is established. 
3.2.6.  Caveats and limitations 
It is not known at this stage whether Atypical BSE prions are amplifiable by cell-free methods. Some 
prion strain types are known to be fairly resistant to amplification by either PMCA or QuIC. 
Concentrated tissues or fluid components can also interfere, notably with QuIC amplification (Wilham 
et al., 2010), sometimes necessitating the use of a PrP
Sc (semi)purification step (Orru et al., 2011; 
Segarra et al., 2013). Blood as a substrate is known to be an issue, making it difficult to apply these 
techniques directly to such samples (Castilla et al., 2005; Lacroux et al., 2014). 
Regarding specifically the PMCA technique, the necessity, so far, to use brain tissue homogenate as a 
substrate  in  order  to  achieve  high  amplification  levels  constitutes  a  limitation.  There  are  also 
significant variations in the laboratory-specific methodologies employed to amplify PrP
Sc, resulting in 
discrepancies or variations in the reproducibility of experiments. Finally, the probability of false-
positives increases as the number of rounds increases (Cosseddu et al., 2011). 
Regarding the QuIC/ASA methods, a confounding aspect is the frequent spontaneous formation of 
recPrP fibrils (without seeding or with seeding at very low concentration) over time, and sometimes 
soon after seeding, which reduces the test specificity (Colby et al., 2007). 
3.3.  Correlation of sensitivity between in vitro amplification and bioassay 
A number of studies have directly compared the performances of cell-free and animal bioassays in 
determining endpoint titrations (Saa et al., 2006; Wilham et al., 2010; Johnson et al., 2012; Makarava 
et  al.,  2012;  Moudjou  et  al.,  2013).  The  sensitivity  achieved  is  generally  superior  to  that  of  the 
bioassay by two to three orders of magnitude (Saa et al., 2006; Johnson et al., 2012; Makarava et al., 
2012; Moudjou et al., 2013). 
This difference has been attributed to a large excess of reactive prion protein seeds with little or no 
infectivity or, alternatively, to the higher rate of clearance of PrP
Sc seeds in animals versus cell-free 
assay reactions. 
Interestingly, while there was a good fit to the Poisson equation for animal infectivity data for two 
TSE agents in hamster (263K and SSLOW) at limiting dilution, the PMCA titration curves for both 
strains showed a more gradual slope than predicted by the Poisson equation, which might be explained 
by the increasing PMCA reaction efficiency at higher dilutions or the fact that inoculum dilution 
results in a concentration-dependent dissociation of aggregates, thereby releasing and increasing the 
concentration of PMCA reactive centres (Makarava et al., 2012). Despite these discrepancies, well-
calibrated PMCA reactions can be an efficient and cost-effective method for the estimation of PrP
Sc 
titre, at least for certain strains. 
3.4.  Concluding remarks 
  The reference method for the estimation of prion infectious titre in tissues is endpoint dilution 
titration in animals. To achieve maximum sensitivity regarding Atypical H-BSE and L-BSE, Atypical BSE study protocol 
 
EFSA Journal 2014;12(7):3798  23 
this bioassay should ideally be done in mouse lines over-expressing bovine PrP
C. Several 
mouse lines over-expressing bovine PrP
C are available worldwide. 
  Several approaches can be used to estimate the infectious titre in a sample using a mouse 
bioassay, depending on the level of infectivity expected in that sample: 
-  In samples containing high and moderate infectivity the most straightforward and accurate 
approach is endpoint titration by the Spearman–Karber method. Although regarded as less 
accurate than the endpoint titration approach, dose–response relationships can be used as a 
method for infectivity estimation when endpoint titration data are not available, provided 
an endpoint titration of a reference inoculum is provided in parallel. 
-  In  the  context  of  a  low  infectious  titre,  incubation  period/attack  rate  and  Poisson 
distribution-derived models are suitable for estimating the infectious titres. 
-  The  amount  of  prion  infectivity  that is  below the threshold  of  detectability  of  mouse 
bioassay but that might be present in the studied tissue can be estimated by assuming a 
Poisson distribution in the response variable. 
  In vitro amplification techniques can be used to determine whether a tissue contains any prion 
seeding activity. 
  These methods are usually more sensitive than the bioassay, and endpoint titration can be 
performed in a format similar to the bioassay. 
  Given  the  current  uncertainties  in  the  specificity  of  these  techniques  and  the  absence  of 
standardisation between laboratories, it is necessary to provide ad-hoc control samples and to 
replicate the experiments to achieve statistical significance. 
  A correlation must be made between the sensitivity achieved by the cell-free assays and the 
bioassays using reference material such as brain tissue from animals at the terminal stage of 
disease. 
4.  Recommended  approach  to  establish  a  laboratory  protocol  to  investigate  presence, 
distribution and infectivity level of Atypical BSE 
The present protocol intends to provide a basis for studies to obtain information on: 
  the distribution of H-BSE and L-BSE agents in the tissues of affected cattle, with special 
emphasis on tissues belonging to the SRM list; 
  the relative amount of H-BSE and L-BSE agents that can be detected in tissues other than 
SRM. 
In the framework of past evaluation of new rapid tests for the detection of TSE in ruminants (EFSA 
BIOHAZ Panel, 2012), EFSA developed a protocol for the evaluation of new rapid BSE post-mortem 
tests (EFSA, 2007). This protocol did not include evaluation of the performance of rapid tests with 
regard  to  Atypical  BSE,  since  at  the  time  no  adequate  material  was  available  to  perform  this 
evaluation. However, it recommended this should be done once H- or L-BSE-infected brain material 
becomes available, and that, if rapid tests do not meet performance criteria on H- and L-BSE, they 
should  not  be  considered  for  field  testing.  Therefore,  in  accordance  with  such  recommendations, 
information should now be obtained on the performance of currently validated rapid tests for TSE 
active surveillance in cattle relative to bioassay for the detection of H-BSE and L-BSE agents. 
4.1.  Selection of tissues 
4.1.1.  BSE infectivity in bovine tissues 
The current SRM list in cattle (see Table 5) has been established and amended in accordance with 
current knowledge related to C-BSE agent distribution in the tissues of infected cattle. Atypical BSE study protocol 
 
EFSA Journal 2014;12(7):3798  24 
The SRM measure is aimed at preventing the entry into the food chain of tissues and anatomical 
structures that might contain significant amounts of infectivity. In the framework of C-BSE infection 
in cattle, these measures are extremely efficient. However, certain tissues that might contain low 
amounts of infectivity in certain BSE-infected cattle are not included in the cattle SRM list (Table 6). 
Table 5:   Bovine SRM list, as defined in Regulation (EC) No 999/2001 
Bovine SRM list 
The skull excluding the mandible and including the brain and eyes, and the spinal cord of animals aged over 12 
months 
The vertebral column excluding the vertebrae of the tail, the spinous and transverse processes of the cervical, 
thoracic and lumbar vertebrae and the median sacral crest and wings of the sacrum, but including the dorsal 
root ganglia, of animals aged over 30 months 
The tonsils, the intestines from the duodenum to the rectum and the mesentery of animals of all ages 
 
Table 6:   Cattle tissues with known infectivity or PrP
Sc presence for C-BSE according to WHO 
(2010), and their inclusion or not in the current SRM list 
  Higher-infectivity tissues  Lower-infectivity tissues 
SRM  Brain 
Dura mater 
Spinal cord 
Optic nerve 
Retina 
Spinal ganglia 
Trigeminal ganglia 
Nictitating membrane 
Autonomic ganglia 
Tonsil 
Ileum 
Jejunum 
Non-SRM    Peripheral nerves 
Adrenal glands 
Bone marrow 
Skeletal muscle 
 
All  the  TSE  agents  replicate  and  accumulate  at  a  high  level  in  the  CNS  and  can  disseminate 
(centrifugally  and  centripetally)  along  the  peripheral  (autonomic  and  motor)  nervous  system. 
However, in a given host the agent distribution and the relative level of infectivity in other tissues can 
vary substantially according to the TSE strain. 
For instance, in humans, although sCJD infectivity is mostly confined to the CNS, numerous lymphoid 
organs have been shown to be infectious  in patients affected with variant CJD (vCJD) (Gill et al., 
2013). 
Similarly, in sheep infected with Classical scrapie, a significant level of infectivity can be found in 
lymphoid organs (about 10
3 times less than in the same weight of brain tissue), whereas in animals 
affected with Atypical scrapie lymphoid organs contain either very low (about 10
7 times less than in 
the same weight of brain tissue) or no detectable infectivity (Andreoletti et al., 2011). 
There are currently no quantitative data on the distribution of H-BSE and L-BSE in cattle tissues. 
4.1.2.  Prioritisation of tissues to be included in further studies 
In  order  to  assess  the  adequacy  and  the  relative  effectiveness  of  the  current  SRM  measures  for 
mitigating  human  dietary  exposure  to  H-BSE  and  L-BSE,  a  large  number  of  tissues/anatomical 
structures need to be tested for the presence of PrP
Sc and/or infectivity. 
Considering the potential number of samples and the requirement for bioassay, the choice of tissues to 
be tested should be prioritised according to three criteria: Atypical BSE study protocol 
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  the level of infectivity they contain in C-BSE-infected cattle (SRM list); 
  the presence of infectivity, or PrP
Sc presence, demonstrated in Atypical BSEs or other TSEs in 
ruminants; 
  the importance in terms of input into the food chain in the EU. 
According to the above criteria, priority categories are defined in Table 7, which also indicates the 
availability of those tissues as a result of the EURL study. 
The final decision regarding the testing of tissues belonging to the different tissue groups will depend 
on the feasibility (cost/number of bioassays) and final objectives of the study. 
Table 7:   Priority categories for tissues to be included in further studies, and availability of the 
tissues as a result of the EURL study 
Priority 1  Priority 2  Priority 3 
Cattle SRM list  Non-SRM with low infectivity (or 
PrP
Sc presence) in ruminants and 
significant
(a) input into the food 
chain 
Non-SRM with low infectivity (or 
PrP
Sc presence) in ruminants and 
limited/no
(a) input into the food 
chain 
Brain (>12 m)  Peripheral nerves (radial nerve
(b), 
sciatic nerve, vagus nerve
(b)) 
Lymph nodes 
Spinal cord (> 12 months)  Thymus  Spleen 
Autonomic ganglia  Abomasum  Oesophagus 
Dorsal root ganglia (> 30 months)  Fore-stomach  Adrenal gland 
Trigeminal ganglia 
(> 12 months) 
Skeletal muscle  Mammary gland 
Splanchnic nerve (mesentery)
(b)  Tongue (muscular tissue)  Nasal mucosa 
Nictitating membrane 
(> 12 months)
(b) 
Bone marrow  Pancreas 
Tonsil  Kidney  Placenta 
Adipose tissue (mesentery)  Liver  Salivary gland 
Caecum  Milk  Blood (whole blood, plasma, red 
blood cells, white blood cells) 
Colon    Cerebrospinal fluid 
Duodenum     
Ileum (Peyer’s patches)     
Ileum (other than Peyer’s patches)     
Jejunum (Peyer’s patches)     
Jejunum (other than Peyer’s 
patches) 
   
Rectum     
Eyes (> 12 months)     
In bold:  tissues  collected  from  the  EURL  study,  available  as  fixed  and  frozen  material  (frozen  only  for  blood  and 
cerebrospinal fluid) (see Table 3). 
(a): Importance of tissues in terms of input in the food chain in the EU as qualitatively estimated by expert opinion. 
(b): Tissues collected from the EURL study, but available only as fixed material (see Table 3). 
 
4.2.  Number of individuals to be tested 
Considering the relatively low number of H-BSE- and L-BSE-infected cattle that are available, and the 
potential  inter-individual  variations  that  might  exist  in  the  distribution/amount  of  TSE  agents  in 
tissues, samples (as identified in Section 4.1.2) collected from at least three H-BSE- and three L-BSE-
infected individuals should be tested. Atypical BSE study protocol 
 
EFSA Journal 2014;12(7):3798  26 
It can be seen from Table 7 that not all the tissues listed were collected from the experimentally 
infected cattle. In order to obtain comprehensive data on all SRM tissues and other non-SRM tissues, 
material collected from other H-BSE and L-BSE cattle would have to be obtained from an alternative 
source,  either  through  new  experimental  inoculation  in  cattle  or  from  other  tissue  banks. 
Consequently, the brain of every animal that is used as a source of biological material for this protocol 
will have to be tested (PrP
Sc detection, bioassay endpoint titration, seeding activity). 
4.3.  Processing of tissues 
In  order  to  avoid  false-positive  results  that  might  occur,  in  particular  using  PrP
Sc  amplification 
methods and bioassay, samples should be collected, handled and prepared under strict TSE sterile 
conditions. 
4.3.1.  Preparation of samples 
Except for the IHC that is carried out using formalin-fixed tissues, all other PrP detection tests and 
bioassay require the preparation of tissue homogenate. 
The homogenisation procedure might affect the performance of certain rapid tests to detect positive 
samples. Consequently, for tissues that are to be tested by rapid tests (CNS) stock macerate (50 % 
weight volume in 5 % glucose solution) should be prepared, aliquoted and stored before processing to 
further experiments (see EFSA (2007)). 
For  other  tissues,  homogenisation  (10 %  weight/volume  homogenate)  should  be  carried  in  a  5 % 
glucose solution. Particular attention should be paid to the quality of homogenisation of material rich 
in connective tissue. 
4.3.2.  Identification of abnormal PrP 
The  PrP
Sc  detection  methods  to  be  applied  must  display  a  sensitivity/specificity  that  is  at  least 
equivalent to that already demonstrated by the EURL. 
4.3.2.1.  Immunohistochemistry  
The IHC protocol to be applied will have to be at least as sensitive as the method used by the EURL. If 
this needs to be established, the EURL will select blocks of brain tissue and skeletal muscle from three 
H-BSE- and three L-BSE-infected cattle that tested positive at the EURL, and brain tissue and skeletal 
muscle from three healthy cattle. The IHC protocol will have to correctly demonstrate at least the 
same extent of PrP
Sc immunolabelling in this panel of samples. 
After this, PrP
Sc IHC detection should be systematically carried out on all the solid tissues listed in 
Table 7. 
4.3.2.2.  Western blotting  
PrP
Sc WB will be applied to tissues according to the requirements defined in Section 4.4. Each sample 
will be tested in duplicate and in two different runs. Results will be considered positive when at the 
least  two  abnormal  PrP  bands  (displaying  equivalent  electromobility  to  that  observed  in  positive 
controls) are identified. 
To ensure that the WB protocol to be applied is adequate, the EURL will prepare 1/10 dilution series 
of 10 % brain homogenates from three H-BSE- and three L-BSE-infected cattle. Dilutions will be 
carried out in healthy cattle brain homogenate. The dilution series will be aliquoted and stored at  
–80 °C by the EURL as reference material. Each dilution series will be tested by WB by the EURL 
using its in-house standard protocol. For each sample, the last positive dilution will be determined. 
Any method to be proposed for the protocol will have to demonstrate a sensitivity at least equivalent 
to that obtained by the EURL. Atypical BSE study protocol 
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4.3.3.  Quantification of seeding activity 
Considering  that  the  methodology  to  be  applied  (PMCA  and  QuIC)  has  not  yet  been  subject  to 
standardisation for testing in routine laboratories, it is not possible at this stage to provide a standard 
operating procedure for conducting this experiment. In particular, the laboratory(ies) in charge of the 
experiment  will  have  to  determine  the  nature  of  the  substrate  (brain  homogenate  from  bovine 
transgenic  mice  for  PMCA  and  recombinant  protein  for  QuIC)  and  the  amplification/fibrilisation 
conditions (temperature/sonication or agitation cycles) that are the most appropriate for conducting the 
experiment. 
Nevertheless, certain recommendations can be provided for performing the experiment: 
  For both L-BSE and H-BSE, the relative sensitivity of the seeding activity should first be 
established  by  comparing  the  results  of  the  endpoint  titration  of  brain  homogenates  by 
bioassay (see Section 4.4) with the last dilution of the same brain material (1/10 dilution 
series) able to provide amplification (PMCA) or fibrilisation of recombinant protein (QuIC). 
  For each tissue, the seeding capacity should be established as the last dilution that is able to 
provide a PrP
res amplification (PMCA) or a fibrilisation of recombinant protein (QuIC). 
  If PMCA is to be used, the samples should be amplified for as many rounds as are necessary 
to reach the amplification plateau without occurrence of any false-positive reaction (due to 
cross-contamination) in negative controls. PrP
res-positive reactions should be tested by WB to 
establish that the banding patterns display features that are typical of H-BSE or L-BSE. 
  If QuIC is to be used, shaking/resting cycles should be continued until the occurrence of the 
first auto-fibrillation in the unseeded control reactions (negative control). 
  In both PMCA and QuIC assays: 
-  in  each  experiment,  a  positive  control  (brain  dilution  corresponding  to  the  already 
established  cut-off  value of the assay)  should  be  run  to  confirm  that  amplification or 
fibrilisation has occurred properly; 
-  each sample should be tested in quadruplicate over two different runs. 
4.3.4.  Bioassay 
Mouse bioassays should preferentially be carried out in over-expressing bovine PrP transgenic mice 
(Tgbov), which are considered to be highly efficient for the detection of bovine prions infectivity (see 
Section 3.1.1). 
If different animal models are used for the bioassay, it should be demonstrated that they display a 
detection sensitivity for H-BSE and L-BSE equivalent to that observed in Tgbov. These results should 
include a comparative endpoint titration of the same dilution series  for H-BSE and L-BSE cattle 
isolates in Tgbov and in the proposed alternative animal model. 
Once the animal model is selected, bioassay testing should be by i.c. inoculation (20 µL per animal). 
Animals should be then be clinically monitored until the occurrence of TSE clinical signs, at which 
time they should be culled. The CNS and spleen samples should be individually collected and tested 
by WB. Half of the brain (including the midline) should be formalin fixed for IHC and vacuolar lesion 
profiling (Beck et al., 2010a; Beck et al., 2010b; Vickery et al., 2013). Animals without typical clinical 
signs should be euthanized at end of life and their brain and spleen tissues must be analyzed similarly. 
Because of the potential thermosensitivity of H- and L-BSE agents, heating of the inocula prior to 
inoculation must be avoided. Atypical BSE study protocol 
 
EFSA Journal 2014;12(7):3798  28 
4.4.  Specific protocol for the three main categories of tissue 
Depending on the type of tissue and the sampling procedure, certain tissues may only be available in 
smaller amounts. This may limit the type and the number of tests that can be carried out. 
In addition, while substantial levels of TSE infectivity/PrP
Sc are likely to be present in certain tissues, 
other tissues are likely to have low or no prion content. 
Table 8 provides a classification of tissues according to infectivity level and amount of tissue usually 
available.  The  protocol  recommended  for  the  three  different  categories  of  tissues  is  presented  in 
sections 4.4.1 to 4.4.3 below. 
Table 8:   Classification of tissues according to infectivity and amount of tissue usually available 
High infectious titre,  
no limitations in quantity 
Low infectious titre expected,  
no limitations in quantity 
Infectivity expected, 
limitations in quantity 
Brain  Lymph nodes  Rectum  Ganglia 
Spinal cord  Spleen  Skeletal muscle  Nerves 
  Thymus  Tongue (muscular)  Nictating membrane 
  Abomasum  Kidney  Tonsils 
  Adipose tissue 
(mesentery) 
Liver  Peyer’s patches 
  Caecum  Mammary gland  Adrenal gland 
  Colon  Nasal mucosa  Bone marrow 
  Duodenum  Pancreas  Eye (retina and optical nerve) 
  Fore-stomach  Placenta  Milk cells 
  Jejunum (other than 
Peyer’s patches) 
Salivary gland  White blood cells 
  Ileum (other than 
Peyer’s patches) 
Blood: whole blood, 
plasma, red blood cells 
 
  Oesophagus  Cerebrospinal fluid   
These two aspects have direct consequences on the final testing protocol that could be applied. 
4.4.1.  Tissues with high infectious titre and no limitations in quantity 
4.4.1.1.  PrP
Sc detetction 
IHC and WB detection should be systematically carried out as described in Section 4.3.2. 
For WB, the last dilution displaying a positive result should be identified. The material used for WB 
should be identical (matched aliquot) to that used for evaluating the rapid tests. 
4.4.1.2.  Bioassay 
An endpoint titration of posterior brainstem homogenate should be carried out by the inoculation of 
groups of six animals with dilutions up to 10
–3, and 12 animals with dilutions from 10
–4 to 10
–10. The 
dilution series should be prepared using material that is identical (aliquot) to that used for evaluating 
the rapid tests. 
The infectious titre in the brainstem of each animal should be established using the Spearman–Karber 
method. Data collected from animals inoculated with the posterior brainstem should be used to define 
a dose–response equation, as described in Arnold et al. (2009), allowing the establishment of the 
relative infectious titre of any other inoculum using the incubation period observed in mice inoculated 
with tissue homogenate. 
In order to obtain information on the potential variation in the infectivity distribution in the brain of H-
BSE and L-BSE-infected cattle, additional bioassays may be carried out. For the spinal cord, thalamus, Atypical BSE study protocol 
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cerebral cortex and cerebellum, groups of six mice could be inoculated with a 10
–2 dilution. This 
experiment could also allow the estimation of the final infectivity load potentially found in the whole 
brain of cattle infected with H-BSE and L-BSE. 
4.4.1.3.  Seeding activity 
Posterior brainstem, spinal cord, thalamus, cerebral cortex and cerebellum 1/10 dilution series should 
be prepared (up to 10
–15) and tested, following the protocol described in Section 4.3.3. The material 
used should be identical to that used for bioassay. At least 20 negative controls (10 unseeded reactions 
and 10 reactions seeded with negative tissue) should be included in each amplification run. 
4.4.1.4.  Performance of rapid tests used in TSE surveillance in cattle 
Rapid PrP
Sc detection assays, when applied to H-BSE and L-BSE detection, should be carried out 
using the brain material collected in the experimental H-BSE and L-BSE cases. 
4.4.2.  Tissues with low infectious titre expected and no limitations in quantity 
4.4.2.1.  PrP
Sc detection 
For solid tissues, IHC and WB detection should be systematically carried out as described in Section 
4.3.2. 
For WB, the samples should initially be tested as a neat homogenate. If WB is positive, a dilution 
series should be prepared, and the last dilution displaying a positive result identified. 
4.4.2.2.  Bioassay 
Tissue homogenates and body fluids should be inoculated in groups of 12 to 18 animals. Inoculation 
should be carried out using the same material (aliquot) as that used for WB. Attack rate and incubation 
period should be used to estimate the infectious titre using the dose–response function established 
using brain material. If no transmission is observed, the maximum infectious titre that could be present 
in the sample will be statistically estimated (see Section 3.1.2). 
4.4.2.3.  Seeding activity 
A 1/10 dilution series will be prepared (up to 10
–10) and tested as described in Section 4.3.3. The 
material to be used should be identical to that used for the bioassay. At least 20 negative controls (10 
unseeded  reactions  and  10  reactions  seeded  with  negative  tissue)  should  be  included  in  each 
amplification run. 
4.4.3.  Tissues with infectivity expected and limitations in quantity 
4.4.3.1.  PrP
Sc detection 
For solid tissues, IHC detection should be systematically carried out as described in Section 4.3.2. 
Because  of  the  limitations  resulting  from  the  volume  of  tissue  homogenate,  no  WB  should  be 
performed in order to preserve the tissues and to prioritise bioassay. 
4.4.3.2.  Bioassay 
Tissues homogenates and body fluids should be inoculated in groups of 12 to 18 animals. Attack rate 
and incubation period should be used to estimate the infectious titre using the dose–response function 
established using brain material. If no transmission is observed, the maximum infectious titre that 
could be present in the sample should be statistically estimated (see Section 3.1.2). Atypical BSE study protocol 
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4.4.3.3.  Seeding activity 
A 1/10 dilution series should be prepared (up to 10
–10) and tested as described in Section 4.3.3. The 
material used should be identical to that used for the bioassay. At least 20 negative controls (10 
unseeded  reactions  and  10  reactions  seeded  with  negative  tissue)  should  be  included  in  each 
amplification run. 
4.5.  Estimation of analyses needed to implement the protocol 
Tables 13–16 in Appendix B provide an estimate of the number of PrP
Sc detection analyses, bioassay 
(number  of  mice  to  be  inoculated)  and  PMCA/QuIC  reactions  to  be  performed  under  different 
scenarios, and give details of the individual tissues to be tested. 
The  first  scenario  considers  the  tissues  obtained  through  the  EURL  study,  while  the  other  three 
scenarios are based on the three tissue categories listed in Table 7, and would give an indication of the 
resources needed according to the three priority levels discussed in Section 4.1.2. 
Table 9 below summarises the overall number of analyses needed. 
Table 9:   Estimation of the overall number of analyses needed per inoculated cow to implement 
the  protocol  under  different  scenarios  (where  appropriate,  minimum  and  maximum  number  of 
analyses is reported). Details of the required analyses for single tissues are provided in Tables 13–16 
in Appendix B 
Scenarios  IHC  WB  Bioassay  Prion seeding 
activity 
reaction 
Tissues obtained from the EURL 
study 
19
(a)  32–160  318–450  1 112 
Priority 1 (cattle SRM list)  21  26–130  294–414  1 024 
Priority 2 (non-SRM with low 
infectivity (or PrP
Sc presence) in 
ruminants and significant input 
into the food chain) 
11  14–70  144–216  528 
Priority 3 (non-SRM with low 
infectivity (or PrP
Sc presence) in 
ruminants and limited/no input into 
the food chain) 
9  24–120  168–252  616 
(a):  IHC analyses have been already carried out in the framework of the EURL study. 
4.6.  Concluding remarks 
  The application of the proposed protocol would provide elements allowing the assessment of 
the relative infectious titre, PrP
Sc accumulation and prion seeding activity in the tissues of 
cattle that developed H-BSE or L-BSE (using posterior brainstem as a reference). 
  Tissues to be covered by further studies are categorised in three priorities, based on their 
inclusion in the cattle SRM list, on the presence of infectivity, or PrP
Sc presence, demonstrated 
in Atypical BSEs or other TSEs in ruminants, and on the importance in terms of input into the 
food chain in the EU. 
  Applying the protocol only to the tissues obtained through the EURL study would provide 
information on some but not all the tissues from the cattle SRM list. It would also provide 
information on some additional tissues not included in the cattle SRM list, but relevant for the 
food chain. 
  Material from other studies could be used to augment the range of SRM and non-SRM tissues 
available. Atypical BSE study protocol 
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  There is no identified source able to provide all the samples necessary to assess infectivity in 
tissues belonging to the full cattle SRM list in H- and L-BSE-infected animals. Therefore, to 
complete this objective, new inoculation of cattle would have to be considered. 
  In  accordance  with  previous  EFSA  recommendations,  through  the  implementation  of  the 
protocol information should also be obtained on the performance of currently validated rapid 
tests for TSE active surveillance in cattle/bioassay for detecting H-BSE and L-BSE agents. 
 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
  Data relating to the prevalence and geographical distribution of Atypical BSE are incomplete. 
  The recent cessation of the testing of healthy slaughtered cattle in some EU Member States 
will lead to a loss of capacity of the monitoring system to detect Atypical BSE cases. 
  For  transmission  studies,  i.c.  challenge  would  be  an  appropriate  proxy  for  studying  the 
distribution of the agent if the origin of the disease was spontaneous, and originating in the 
brain, while oral challenge would be more appropriate if the origin of the disease was through 
ingestion of infected material. 
  The current lack of information on the distribution of infectivity in tissues of Atypical BSE-
infected cattle does not allow judgement of whether the current list of bovine SRM, set by EU 
legislation based on data relating to the pathogenesis and tissue distribution of C-BSE, is fit 
for the purpose of removing most of the Atypical BSE infectivity from bovine carcasses. 
  Where data exist from both field cases and experimental animals (i.e. for L-BSE only), there is 
good agreement of the data with regard to abnormal PrP distribution. There are no data for 
field case H-BSE. 
  Disease-related PrP has been reported consistently in CNS tissues, peripheral ganglia and 
nerves, muscles (predominantly muscle spindles), adrenal glands and retina for both H-BSE 
and L-BSE. All of these tissues are also positive in C-BSE. 
  By contrast with C-BSE, at this stage no lymphoid tissues or gastrointestinal tissues from H-
BSE-  and  L-BSE-affected  animals  have  tested  positive  for  PrP
Sc  presence  (IHC,  WB)  or 
infectivity (bioassay). 
  The reference method for the estimation of prion infectious titre in tissues is endpoint dilution 
titration in animals. To achieve maximum sensitivity regarding Atypical H-BSE and L-BSE, 
this bioassay should ideally be done in mouse lines over-expressing bovine PrP
C. Several 
mouse lines over-expressing bovine PrP
C are available worldwide. 
  In vitro amplification techniques can be used to determine whether a tissue contains any 
prion seeding activity. A correlation must be made between the sensitivity achieved by the 
cell-free assays and bioassays using reference material such as brain tissue from animals at 
the terminal stage of disease. 
  The application of the proposed protocol would provide elements allowing the assessment of 
the relative infectious titre, PrP
Sc accumulation and prion seeding activity in the tissues of 
cattle that developed H-BSE or L-BSE (using posterior brainstem as a reference). 
  Tissues to be covered by further studies are categorised in three priorities, based on their 
inclusion in the cattle SRM list, on the presence of infectivity, or PrP
Sc presence, demonstrated 
in Atypical BSEs or other TSEs in ruminants, and on the importance in terms of input into the 
food chain in the EU. Atypical BSE study protocol 
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  Applying the protocol only to the tissues obtained through the EURL study would provide 
information on some but not all the tissues from the cattle SRM list. It would also provide 
information on some additional tissues not included in the cattle SRM list, but relevant for the 
food chain. 
  Material from other studies could be used to augment the range of SRM and non-SRM tissues 
available. 
  There is no identified source able to provide all the samples necessary to assess infectivity in 
tissues belonging to the full cattle SRM list in H- and L-BSE-infected animals. Therefore, to 
complete this objective, new inoculations of cattle would have to be considered. 
RECOMMENDATIONS 
  In  accordance  with  former  EFSA  recommendations,  through  the  implementation  of  the 
protocol information should also be obtained on the performance of currently validated rapid 
tests for TSE active surveillance in cattle/bioassay for detecting H-BSE and L-BSE agents. 
  If new inoculation experiments are carried out in cattle with H-BSE and L-BSE, the following 
should be considered: 
-  inoculation through both the i.c. and oral route (despite the potential length of the oral 
route experiment); 
-  inclusion of C-BSE controls in the i.c. route experiment; 
-  sequential time killing of animals; 
-  collection of all tissues listed in Table 7. 
DOCUMENTATION PROVIDED TO EFSA 
1.  Summary of the samples available and the tests already carried out by the EURL-TSE. Submitted 
by the European Commission as Annex 1 to the mandate. 
2.  Information on protocols and tests results provided by the EURL-TSE. Submitted by the European 
Commission as Annex 2 to the mandate. 
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APPENDICES 
Appendix A.   Data from published studies on Atypical BSE and Classical BSE positivity 
Table 10:   Data available from published studies on H-BSE  
Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Okada et al. 
(2011, 2013) 
Greenlee et al. 
(2012) 
TSE type  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE 
Challenge status  i.c. challenge   i.c. challenge  i.c. challenge  i.c. challenge  i.c. challenge  i.c. challenge  i.c. challenge  i.c. challenge  i.c. challenge 
Animal ID  PG0384/10  PG1129/10  PG0373/10  PG0006/13  PG0782/10  PG0106/13  FLI-RA10, 13, 14, 
15, 16  7749, 9458, 0728    
Breed  Aberdeen Angus 
X 
Aberdeen Angus 
X 
Aberdeen Angus 
X  Hereford X  Aberdeen Angus 
X  Hereford X  Holstein-Friesian  Holstein  E211K genotype 
Sex  F  M  M  M  M  F  F  F(2), M(1)  F 
Donor  French field case  French field case  French field case  sub-passage of 
373/10  French field case  sub-passage of 
782/10 
German field case 
R152/04 
Canadian H- 
BSE Charolais 
cross  
2006 U.S. H-type 
BSE case 
associated with 
the E211K 
polymorphism 
Age at challenge   11 months  10 months 
2 weeks 
10 months 
3 weeks 
7 months 
1 week  11 months  7 months 
1 week  6 months  3-4 months  2 months 
Incubation period (days) - all 
animals left to develop to clinical 
end-point 
559  582  526  505  649  525  365 early clinical, 
419, 428, 475, 482  559.7 ± 47.2   288 
Central nervous system                            
brain  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB 
spinal cord  IHC/WB  IHC  IHC     IHC     IHC/WB  IHC/WB  IHC 
Peripheral nervous system                            
Ganglia and plexi                            
aorticorenal ganglion                            
brachial plexus                       IHC/WB    
caudal cervical vertebral ganglion                            
caudal mesenteric ganglion                            
coeliacomesenteric ganglion                       IHC/WB    
cranial cervical ganglion                       IHC/WB    
cranial mesenteric ganglion                            
dorsal root ganglion                       IHC/WB    
middle cervical ganglion                            
nodose ganglion                            
pelvic plexus                            
stellate ganglion                       IHC/WB    
thoracic vertebral ganglion                            
trigeminal Ganglia  IHC  IHC  IHC     IHC        IHC/WB  IHC Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Okada et al. 
(2011, 2013) 
Greenlee et al. 
(2012) 
TSE type  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE 
Nerves                            
accessory nerve                       IHC/WB    
facial nerve                       IHC/WB    
hypoglossal nerve                       IHC/WB    
median nerve                       IHC/WB    
optic nerve                        IHC/WB  IHC 
phrenic nerve                       IHC/WB    
radial nerve                       IHC/WB    
sciatic nerve                       IHC/WB  IHC 
splanchnic nerve                            
suprascapular nerve                       IHC/WB    
tibial nerve                       IHC/WB    
trigeminal nerve                          IHC 
vagus nerve                       IHC/WB    
vagosympathetic trunk                       IHC/WB    
peripheral nerves (unsp)                            
Lymphoid tissue                             
anterior cervical LN                            
axillary LN                       IHC/WB    
brachiocephalic LN                       IHC/WB    
cervical LN                        IHC/WB    
cervical Thymus                       IHC/WB    
external iliac LN                       IHC/WB    
GALT (various locations)                            
hepatic LN                       IHC/WB    
ileocaecal LN                            
internal iliac LN                       IHC/WB    
lateral retropharyngeal LN                       IHC/WB  IHC 
lymph node (unsp)                             
medial retropharyngeal LN  IHC  IHC  IHC     IHC           IHC 
mesenteric LN  IHC  IHC  IHC     IHC        IHC/WB  IHC 
nictitating membrane                            
palatine tonsil  IHC  IHC  IHC     IHC        IHC/WB  IHC 
parotid LN                       IHC/WB    
popliteal LN                       IHC/WB  IHC 
prefemoral LN                            
prescapular LN                          IHC 
RAMALT                            
splenic LN                            
subiliac LN                       IHC/WB    
submandibular LN                       IHC/WB    
suprainguinal LN                       IHC/WB    Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Okada et al. 
(2011, 2013) 
Greenlee et al. 
(2012) 
TSE type  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE 
spleen                       IHC/WB    
Gastrointestinal tissues                            
abomasum                          IHC 
adipose tissue (mesenteric)                            
caecum                            
colon                            
colon (Peyer's patches)                            
cranial oesophagus                          IHC 
distal ileum (Peyer's patches)  IHC  IHC  IHC     IHC             
duodenum                            
ileocaecal plica (Peyer's patches)                            
ileocaecal valve                            
ileum (no Peyer's patches)                             
ileum (unsp)                           IHC 
jejunum (no Peyer's patches)                             
jejunum (Peyer's patches)                            
jejunum (unsp)                             
omasum                          IHC 
rectum (Peyer's patches)                            
rectum                            
reticulum                          IHC 
rumen                          IHC 
small intestine (unsp)                            
large intestine (unsp)                            
Muscles                             
biceps                            
deltoid                             
diaphragm                          IHC 
ext abdominal oblique                             
ext carpi radialis                             
ext carpi ulnaris                             
extraocular   IHC  IHC  IHC     IHC             
gastrocnemius                             
gracilis                             
heart                           IHC 
intercostal                             
lat digital extensor                             
longissimus dorsi                            
masseter                          IHC 
medial gluteal   IHC
(a)  IHC
(a)  IHC
(a)     IHC
(a)             
pectoral                             
peroneus                             Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Okada et al. 
(2011, 2013) 
Greenlee et al. 
(2012) 
TSE type  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE  H-BSE 
psoas                             
semimembranosus                             
semitendinosus  IHC
(a)  IHC
(a)  IHC
(a)     IHC
(a)             
tensor fasciae latae                             
tongue                          IHC 
trapezius                             
triceps  IHC
(a)  IHC
(a)  IHC     IHC
(a)             
other muscles (unsp)                            
Other tissues                            
adrenals                       IHC/WB  IHC 
aorta                          IHC 
bladder                           IHC 
bone marrow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eye                    (retina)  (retina) IHC/WB  (retina) IHC 
kidney                          IHC 
liver                          IHC 
lung                          IHC 
mammary gland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nasal mucosa                          IHC 
oral mucosa                            
parotid salivary gland                            
skin                          IHC 
submandibular salivary gland                            
thyroid                          IHC 
uterus                            
Body fluids                            
buffy coat (citrate)                            
buffy coat (EDTA)                            
cerebrospinal fluid                            
milk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
plasma (citrate)                            
plasma (EDTA)                            
serum                            
whole blood (citrate)                            
whole blood (EDTA)                            
 
Red 
Blue 
Shaded grey 
unsp 
(a) 
positive result with method indicated 
negative result with method indicated 
tissue available 
unspecified 
negative but no muscle spindles in the sample 
GALT 
IHC 
LN 
PMCA 
RAMALT 
WB 
gut-associated lymphoid tissue 
immunohistochemistry 
lymph node 
protein misfolding cyclic amplification 
rectoanal mucosa-associated lymphoid tissue 
Western blotting Atypical BSE study protocol 
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Table 11:   Data available from published studies on L-BSE 
Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by 
EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Fukuda et al. 
(2009); Iwamaru 
et al. (2010) 
Mazza et al. 
(2007); Suardi 
et al. (2012) 
Suardi et 
al. (2012) 
Casalone et 
al. (2004) 
TSE type  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE 
Challenge status  i.c. 
challenge 
i.c. 
challenge 
i.c. 
challenge 
i.c. 
challenge 
i.c. 
challenge 
i.c. 
challenge  i.c. challenge  i.c. challenge  i.c. challenge   i.c. challenge   field case  field case  field case 
Animal ID  PG1148/10  PG1345/10  PG0323/10  PG0101/13  PG1346/10  PG0107/13  FLI-RA01 to 06  254-F, 259-F, 
261-F 
816-Ab, 994-Ab, 
995-Ab 
528, 1061, 5566 
(8515, 486 
preclinical) 
12966/07  126752/09  141387 
Breed  Aberdeen 
Angus X 
Aberdeen 
Angus X 
Aberdeen 
Angus X  Hereford X  Aberdeen 
Angus X  Hereford X  Holstein-Friesian  Holstein-Friesian 
(3)  Alpine brown (3)  Holstein (5)  Piemontese (14y, 
3
rd BASE case) 
Holstein-
Freisian 
Bruna alpina 
(2
nd L-BSE 
field case) 
Sex  F  F  M  M  M  F  F              F    
Donor 
Italian field 
case 
(141387) 
Italian field 
case 
(141387) 
Italian field 
case 
(141387) 
sub-
passage of 
323/10 
Italian field 
case 
(141387) 
sub-
passage of 
1346/10 
German field case 
R172/02 
BASE-affected 
Piemontese 
(code #1088) 
BASE-affected 
Piemontese 
(code #1088) 
aged Japanese 
Black cow JP24  NA  NA    
Age at challenge   10 months 1 
week 
10 months 2 
weeks 
10 months 1 
week 
7 months 1 
week 
10 months 2 
weeks 
7 months 1 
week  6 months  4 months  4 months  2-3 months  NA  NA    
Incubation period (days) - all 
animals left to develop to 
clinical end-point 
587  649  532  525  690  586 
160 preclinical, 353, 
417 early clinical, 
466, 479, 489 
461, 470, 480  525, 530, 551  486 ± 11          
Central nervous system                                        
brain  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB  IHC/WB/bioassay  IHC/WB  IHC/WB/bioassay     IHC/WB 
spinal cord  IHC  IHC  IHC     IHC     IHC/WB  IHC/WB  IHC/WB  WB  IHC/WB       
Peripheral nervous system                                        
Ganglia and plexi                                        
aorticorenal ganglion                                        
brachial plexus                             WB          
caudal cervical vertebral ganglion                                        
caudal mesenteric ganglion                                        
coeliacomesenteric ganglion                                        
cranial cervical ganglion                                        
cranial mesenteric ganglion                             WB          
dorsal root ganglion                                        
middle cervical ganglion                             WB          
nodose ganglion                                        
pelvic plexus                                        
stellate ganglion                             WB          
thoracic vertebral ganglion                                        
trigeminal ganglia  IHC (inc)  IHC  IHC (inc)     IHC              WB          
Nerves                                        
accessory nerve                             WB          
facial nerve                             WB          
hypoglossal nerve                             WB          Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by 
EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Fukuda et al. 
(2009); Iwamaru 
et al. (2010) 
Mazza et al. 
(2007); Suardi 
et al. (2012) 
Suardi et 
al. (2012) 
Casalone et 
al. (2004) 
TSE type  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE 
median nerve                             WB          
optic nerve                              WB  WB       
phrenic nerve                             WB          
radial nerve                             WB          
sciatic nerve                             WB          
splanchnic nerve                                        
suprascapular nerve                             WB          
tibial nerve                             WB          
trigeminal nerve                                        
vagus nerve                             WB          
vagosympathetic trunk                             WB          
peripheral nerves (unsp)                       IHC/WB  IHC/WB     IHC/WB       
Lymphoid tissue                                         
anterior cervical LN                             WB          
axillary LN                             WB          
brachiocephalic LN                             WB          
cervical LN                        IHC/WB  IHC/WB             
cervical Thymus                       IHC/WB  IHC/WB             
external iliac LN                             WB          
GALT (various locations)                                IHC/WB       
hepatic LN                             WB          
ileocaecal LN                                IHC/WB       
internal iliac LN                             WB          
lateral retropharyngeal LN                             WB          
lymph node (unsp)                           bioassay             
medial retropharyngeal LN  IHC  IHC  IHC     IHC                         
mesenteric LN  IHC  IHC  IHC     IHC        IHC/WB  IHC/WB/bioassay  WB  IHC/WB       
nictitating membrane                                IHC/WB       
palatine tonsil  IHC  IHC  IHC     IHC              WB          
parotid LN                             WB          
popliteal LN                             WB          
prefemoral LN                                        
prescapular LN                                        
RAMALT                                IHC/WB       
splenic LN                             WB          
subiliac LN                             WB          
submandibular LN                             WB          
suprainguinal LN                             WB          
spleen                       IHC/WB  IHC/WB  WB  IHC/WB/bioassay       
Gastrointestinal tissues                                        
abomasum                                        
adipose tissue (mesenteric)                                        Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by 
EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Fukuda et al. 
(2009); Iwamaru 
et al. (2010) 
Mazza et al. 
(2007); Suardi 
et al. (2012) 
Suardi et 
al. (2012) 
Casalone et 
al. (2004) 
TSE type  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE 
caecum                                        
colon                                        
colon (Peyer's patches)                                        
cranial oesophagus                                        
distal ileum (Peyer's patches)  IHC  IHC  IHC     IHC                         
duodenum                                        
ileocaecal plica (Peyer's patches)                                        
ileocaecal valve                                IHC/WB       
ileum (no Peyer's patches)                                         
ileum (unsp)                                 IHC/WB       
jejunum (no Peyer's patches)                                         
jejunum (Peyer's patches)                                        
jejunum (unsp)                                 IHC/WB       
omasum                                IHC/WB       
rectum (Peyer's patches)                                        
rectum                                        
reticulum                                        
rumen                                IHC/WB       
small intestine (unsp)                                        
large intestine (unsp)                                        
Muscles                                         
biceps                                   IHC    
deltoid                           IHC             
diaphragm                                        
ext abdominal oblique                                    IHC    
ext carpi radialis                                    IHC    
ext carpi ulnaris                                    IHC    
extraocular   IHC  IHC  IHC     IHC                         
gastrocnemius                           IHC             
gracilis                                    IHC    
heart                                 IHC/WB       
intercostal                                 IHC/WB/bioassay   IHC    
lat digital extensor                                    IHC    
longissimus dorsi                       IHC  IHC/bioassay        IHC    
masseter                                IHC/WB       
medial gluteal   IHC
(a)  IHC
(a)  IHC
(a)     IHC           IHC     bioassay       
pectoral                           IHC        IHC    
peroneus                                    IHC    
psoas                           IHC             
semimembranosus                                    IHC    
semitendinosus  IHC
(a)  IHC
(a)  IHC
(a)     IHC
(a)                    IHC    
tensor fasciae latae                                    IHC    Atypical BSE study protocol 
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Reference  EURL study 
(based on Konold et al. (2012) and other unpublished data provided by 
EURL in the framework of this mandate) 
Buschmann et al. 
(2011a, b); Hoffman 
et al. (2007) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Lombardi et al. 
(2008); Suardi 
et al. (2012) 
Fukuda et al. 
(2009); Iwamaru 
et al. (2010) 
Mazza et al. 
(2007); Suardi 
et al. (2012) 
Suardi et 
al. (2012) 
Casalone et 
al. (2004) 
TSE type  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE  L-BSE 
tongue                                IHC/WB       
trapezius                                    IHC    
triceps  IHC
(a)  IHC
(a)  IHC     IHC
(a)        IHC/WB  IHC/WB        IHC    
other muscles (unsp)                       IHC/WB  IHC/WB     IHC/WB       
Other tissues                                        
adrenals                             WB          
aorta                                IHC/WB       
bladder                                 IHC/WB       
bone marrow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eye                    (retina)                   
kidney                          bioassay      IHC/WB/bioassay       
liver                       IHC/WB  IHC/WB     IHC/WB       
lung                       IHC/WB  IHC/WB             
mammary gland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  IHC/WB 
 
 
 
 
nasal mucosa                                IHC/WB       
oral mucosa                                IHC/WB       
parotid salivary gland                                        
skin                                        
submandibular salivary gland                                        
thyroid                                        
uterus                                IHC/WB       
Body fluids                                        
buffy coat (citrate)                                        
buffy coat (EDTA)                                        
cerebrospinal fluid                                        
milk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
plasma (citrate)                                        
plasma (EDTA)                                        
serum                                        
whole blood (citrate)                                        
whole blood (EDTA)                                        
 
Red 
Blue 
Shaded grey 
unsp 
(a) 
 
positive result with method indicated 
negative result with method indicated 
tissue available 
unspecified 
negative but no muscle spindles in the sample 
GALT 
IHC 
inc 
LN 
RAMALT 
WB 
 
gut-associated lymphoid tissue 
immunohistochemistry 
inconclusive result 
lymph node 
rectoanal mucosa-associated lymphoid tissue 
Western blotting 
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Table 12:   Data available from published studies on C-BSE 
Reference  Buschmann and Groschup (2005); Balkema-Buschmann et al. 
(2011a); Fast et al. (2013); Franz et al. (2012); Fukudaet al. 
(2012); Hoffmann et al. (2011); Iwata et al. (2006); Kaatz et al. 
(2012); Masujin et al. (2007); Okada et al. (2013); Stack et al. 
(2011); Terry et al. (2003); Wells et al. (2005) 
TSE type  C-BSE 
Challenge status  experimental and field cases 
Animal ID  various 
Breed  various 
Sex  various 
Donor  various 
Age at challenge   various 
Incubation period (days) - all animals left to develop to clinical end-point  various 
Central nervous system    
brain  IHC/WB/Bioassay 
spinal cord  IHC/WB/Bioassay 
Peripheral nervous system    
Ganglia and plexi    
aorticorenal ganglion    
brachial plexus    
caudal cervical vertebral ganglion  bioassay 
caudal mesenteric ganglion  IHC/bioassay 
coeliacomesenteric ganglion  IHC/bioassay/PMCA 
cranial cervical ganglion  IHC/bioassay 
cranial mesenteric ganglion    
dorsal root ganglion  WB/PMCA 
middle cervical ganglion    
nodose ganglion  IHC/bioassay 
pelvic plexus    
stellate ganglion  IHC/WB/bioassay/PMCA 
thoracic vertebral ganglion    
trigeminal ganglia  IHC/bioassay 
Nerves    
accessory nerve    
facial nerve  bioassay 
hypoglossal nerve    
median nerve    
optic nerve   bioassay/PMCA 
phrenic nerve  WB 
radial nerve  WB/bioassay 
sciatic nerve  WB/bioassay 
splanchnic nerve  IHC/bioassay 
suprascapular nerve    
tibial nerve    
trigeminal nerve    
vagus nerve  IHC/WB/bioassay 
vagosympathetic trunk    
peripheral nerves (unsp)    
Lymphoid tissue     
anterior cervical LN    
axillary LN  WB 
brachiocephalic LN    
cervical LN   WB 
cervical Thymus    
external iliac LN    
GALT (various locations)    
hepatic LN    
ileocaecal LN    
internal iliac LN  WB 
lateral retropharyngeal LN  PMCA 
lymph node (unsp)     
medial retropharyngeal LN    
mesenteric LN  bioassay 
nictitating membrane    
palatine tonsil  bioassay/PMCA 
parotid LN    
popliteal LN  PMCA Atypical BSE study protocol 
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Reference  Buschmann and Groschup (2005); Balkema-Buschmann et al. 
(2011a); Fast et al. (2013); Franz et al. (2012); Fukudaet al. 
(2012); Hoffmann et al. (2011); Iwata et al. (2006); Kaatz et al. 
(2012); Masujin et al. (2007); Okada et al. (2013); Stack et al. 
(2011); Terry et al. (2003); Wells et al. (2005) 
TSE type  C-BSE 
prefemoral LN    
prescapular LN    
RAMALT    
splenic LN    
subiliac LN    
submandibular LN    
suprainguinal LN  WB 
spleen  bioassay/PMCA 
Gastrointestinal tissues    
abomasum  PMCA 
adipose tissue (mesenteric)    
caecum    
colon    
colon (Peyer's patches)    
cranial oesophagus  PMCA 
distal ileum (Peyer's patches)  IHC/WB/bioassay/PMCA 
duodenum  IHC/WB 
ileocaecal plica (Peyer's patches)    
ileocaecal valve  IHC/bioassay 
ileum (no Peyer's patches)     
ileum (unsp)     
jejunum (no Peyer's patches)     
jejunum (Peyer's patches)  IHC/WB/bioassay/PMCA 
jejunum (unsp)     
omasum    
rectum (Peyer's patches)    
rectum  PMCA 
reticulum    
rumen  PMCA 
small intestine (unsp)    
large intestine (unsp)    
Muscles     
biceps  PMCA 
deltoid     
diaphragm    
ext abdominal oblique     
ext carpi radialis     
ext carpi ulnaris     
extraocular     
gastrocnemius     
gracilis     
heart   bioassay 
intercostal   IHC/WB 
lat digital extensor     
longissimus dorsi  bioassay/PMCA 
masseter  IHC/WB 
medial gluteal     
pectoral     
peroneus     
psoas   IHC/WB/PMCA 
semimembranosus     
semitendinosus  IHC/WB/ bioassay/PMCA 
tensor fasciae latae     
tongue  bioassay/PMCA 
trapezius     
triceps  IHC/WB 
other muscles (unsp)  IHC/WB (quadriceps) 
Other tissues    
adrenals  WB/bioassay/PMCA 
aorta    
bladder     
bone marrow  bioassay/PMCA 
eye  bioassay 
kidney    
liver    Atypical BSE study protocol 
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Reference  Buschmann and Groschup (2005); Balkema-Buschmann et al. 
(2011a); Fast et al. (2013); Franz et al. (2012); Fukudaet al. 
(2012); Hoffmann et al. (2011); Iwata et al. (2006); Kaatz et al. 
(2012); Masujin et al. (2007); Okada et al. (2013); Stack et al. 
(2011); Terry et al. (2003); Wells et al. (2005) 
TSE type  C-BSE 
lung    
mammary gland    
nasal mucosa  bioassay 
oral mucosa    
parotid salivary gland    
skin    
submandibular salivary gland    
thyroid    
uterus    
Body fluids    
buffy coat (citrate)    
buffy coat (EDTA)    
cerebrospinal fluid  bioassay 
milk  bioassay 
plasma (citrate)    
plasma (EDTA)    
serum    
whole blood (citrate)    
whole blood (EDTA)    
Red 
Blue 
Shaded grey 
GALT 
IHC 
LN 
PMCA 
RAMALT 
WB 
unsp 
(a) 
positive result with method indicated 
negative result with method indicated 
tissue available 
gut-associated lymphoid tissue 
immunohistochemistry 
lymph node 
protein misfolding cyclic amplification 
rectoanal mucosa-associated lymphoid tissue 
Western blotting 
unspecified 
negative but no muscle spindles in the sample 
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Appendix B.   Estimation of the number of analyses needed to implement the protocol 
Table 13:   Estimation  of  the  number  of  analyses  needed  per  inoculated  cow  to  implement  the 
protocol  on  tissues  obtained  from  the  EURL  study  (where  appropriate,  minimum  and  maximum 
number of analyses is reported) 
Tissue  IHC
(a)  WB  Bioassay  Prion seeding 
activity reaction 
Brain (> 12 m): cerebellum  1  2–10  0–6  64 
Brain (> 12 m): cortex  1  2–10  0–6  64 
Brain (> 12 m): posterior brainstem  1  2–10  102  64 
Brain (> 12 m): thalamus  1  2–10  0–6  64 
Spinal cord  1  2–10  0–6  64 
Trigeminal ganglia (> 12 m)  1  0  12–18  44 
Peripheral nerves: sciatic  1  0  12–18  44 
Lymph nodes  1  2–10  12–18  44 
Tonsil  1  0  12–18  44 
Spleen  1  2–10  12–18  44 
Thymus  1  2–10  12–18  44 
Ileum (Peyer’s patches)  1  0  12–18  44 
Jejunum (Peyer’s patches)  1  0  12–18  44 
Oesophagus  1  2–10  12–18  44 
Skeletal muscle  1  2–10  12–18  44 
Adrenal gland  1  0  12–18  44 
Eyes (> 12 m)  1  2–10  12–18  44 
Kidney  1  2–10  12–18  44 
Salivary gland  1  2–10  12–18  44 
Blood: plasma  NA  2–10  12–18  44 
Blood: white blood cells  NA  0  12–18  44 
Blood: whole blood  NA  2–10  12–18  44 
Cerebrospinal fluid  NA  2–10  12–18  44 
Total per inoculated cow  19  32–160  318–450  1 112 
(a):  IHC analyses have been already carried out in the framework of the EURL study. 
NA: not applicable: analysis cannot be performed on this type of tissue. 
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Table 14:   Estimation  of  the  number  of  analyses  needed  per  inoculated  cow  to  implement  the 
protocol on tissues included in the cattle SRM list (Priority 1) (where appropriate, minimum and 
maximum number of analyses is reported) 
Tissue
(a)  IHC  WB  Bioassay  Prion seeding 
activity reaction 
Brain (> 12 m): cerebellum  1  2–10  0–6  64 
Brain (> 12 m): cortex  1  2–10  0–6  64 
Brain (> 12 m): posterior brainstem  1  2–10  102  64 
Brain (> 12 m): thalamus  1  2–10  0–6  64 
Spinal cord  1  2–10  0–6  64 
Autonomic ganglia  1  0  12–18  44 
Dorsal root ganglia (> 30 m)  1  0  12–18  44 
Trigeminal ganglia (> 12 m)  1  0  12–18  44 
Nictitating membrane  1  0  12–18  44 
Tonsil  1  0  12–18  44 
Adipose tissue (mesentery)  1  2–10  12–18  44 
Caecum  1  2–10  12–18  44 
Colon  1  2–10  12–18  44 
Duodenum  1  2–10  12–18  44 
Ileum (Peyer’s patches  1  0  12–18  44 
Ileum (other than Peyer’s patches)  1  2–10  12–18  44 
Jejunum (Peyer’s patches)  1  0  12–18  44 
Jejunum (other than Peyer’s patches)  1  2–10  12–18  44 
Rectum  1  2–10  12–18  44 
Splanchnic nerves (mesentery)  1  0  12–18  44 
Eyes (> 12 m)  1  2–10  12–18  44 
Total per inoculated cow  21  26–130  294–414  1 024 
(a): provided that an appropriate quantity of tissue is/remains available when the study is initiated 
Table 15:   Estimation  of  the  number  of  analyses  needed  per  inoculated  cow  to  implement  the 
protocol on tissues not included in the cattle SRM list, with low infectivity (or PrP
Sc presence) in 
ruminants and significant input into the food chain (Priority 2) (where appropriate, minimum and 
maximum number of analyses is reported) 
Tissue
(a)  IHC  WB  Bioassay  Prion seeding 
activity reaction 
Peripheral nerves: radial  1  0  12–18  44 
Peripheral nerves: sciatic  1  0  12–18  44 
Peripheral nerves: vagus  1  0  12–18  44 
Thymus  1  2–10  12–18  44 
Abomasum  1  2–10  12–18  44 
Fore-stomach  1  2–10  12–18  44 
Skeletal muscle  1  2–10  12–18  44 
Tongue (muscular)  1  2–10  12–18  44 
Bone marrow  1  0  12–18  44 
Kidney  1  2–10  12–18  44 
Liver  1  2–10  12–18  44 
Milk cells  NA  0  12–18  44 
Total per inoculated cow  11  14–70  144–216  528 
(a):  provided that an appropriate quantity of tissue is/remains available when the study is initiated 
NA: not applicable: analysis cannot be performed on this type of tissue. Atypical BSE study protocol 
 
EFSA Journal 2014;12(7):3798  55 
Table 16:   Estimation  of  the  number  of  analyses  needed  per  inoculated  cow  to  implement  the 
protocol on tissues not included in the cattle SRM list, with low infectivity (or PrP
Sc presence) in 
ruminants and limited/no input into the food chain (Priority  3) (where appropriate, minimum and 
maximum number of analyses is reported) 
Tissue
(a)  IHC  WB  Bioassay  Prion seeding 
activity reaction 
Spleen  1  2–10  12–18  44 
Lymph nodes  1  2–10  12–18  44 
Oesophagus  1  2–10  12–18  44 
Adrenal gland  1  0  12–18  44 
Salivary gland  1  2–10  12–18  44 
Mammary gland  1  2–10  12–18  44 
Nasal mucosa  1  2–10  12–18  44 
Pancreas  1  2–10  12–18  44 
Placenta  1  2–10  12–18  44 
Blood: plasma  NA  2–10  12–18  44 
Blood: red blood cells  NA  2–10  12–18  44 
Blood: white blood cells  NA  0  12–18  44 
Blood: whole blood  NA  2–10  12–18  44 
Cerebrospinal fluid  NA  2–10  12–18  44 
Total per inoculated cow  9  24–120  168–252  616 
(a):  provided that an appropriate quantity of tissue is/remains available when the study is initiated. 
NA:  not applicable: analysis cannot be performed on this type of tissue. 
 